Sequencing results	Number of total raw reads	60,866,926

 	Number of total clean reads	51,606,364

 	Number of total clean nucleotides (nt)	4,644,572,760

 	Q20 percentage of total clean reads	95.92%

 	GC percentage of total clean nucleotides	51.26%

 	N percentage of total clean nucleotides	0.00%

Assembling results	Number of unigenes	38,504 (5,372 into distinct clusters; 33,132 singletons)

 	Total length (nt) of total unigenes	21,977,286

 	Mean length (nt) of total unigenes	571

 	N50 (nt) of total unigenes	711

Annotation	Unigenes with Nr database	25,456 (66% of 38,504 unigenes)

(E-value < =1e-5)	Unigenes with Nt database	20,554 (53%)

 	Unigenes with Swiss-Prot database	17,651 (46%)

 	Unigenes with KEGG database	16,622 (43%), 257 pathways

 	Unigenes with COG database	7,204 (19%), 25 functional categories

 	Unigenes with GO database	16,588 (43%), 62 subcategories grouped to 3 main categories

 	Biological process	27 sub-categories

 	Cellular component	17 sub-categories

 	Molecular function	18 sub-categories

 	Total unigenes annotated	26,650 (69% of 38,504 unigenes)

Sequencing results	Number of total raw reads	60,866,926

	Number of total clean reads	51,606,364

	Number of total clean nucleotides (nt)	4,644,572,760

	Q20 percentage of total clean reads	95.92%

	GC percentage of total clean nucleotides	51.26%

	N percentage of total clean nucleotides	0.00%

Assembling results	Number of unigenes	38,504 (5,372 into distinct clusters; 33,132 singletons)

	Total length (nt) of total unigenes	21,977,286

	Mean length (nt) of total unigenes	571

	N50 (nt) of total unigenes	711

Annotation	Unigenes with Nr database	25,456 (66% of 38,504 unigenes)

(E-value < =1e-5)	Unigenes with Nt database	20,554 (53%)

	Unigenes with Swiss-Prot database	17,651 (46%)

	Unigenes with KEGG database	16,622 (43%), 257 pathways

	Unigenes with COG database	7,204 (19%), 25 functional categories

	Unigenes	16,588 (43%), 62 subca

Sequencing results	Number of total raw reads	60,866,926

	 with GO database	tegories grouped to 3 main categories

	Biological process	27 sub-categories

	Cellular component	17 sub-categories

	Molecular function	18 sub-categories

	Total unigenes annotated	26,650 (69% of 38,504 unigenes)


		"gold standard" = result of sentinel node biopsy

		occult metastatic disease: Yes	occult metastatic disease: No

new predictive marker for occult metastatic disease (ECAD)	Low ECAD	true positive	false positive	all test positives

	expression	a	b	a + b

	High ECAD	c	d	all test

	expression	false negative	true negative	negatives

				c + d

		a + c	b + d

		all with occult	all without occult

		disease	disease

		"gold standard" = result of sentinel node biopsy

	expression	a	b	a + b

	High ECAD	c	d	all test

	expression	false negative	true negative	negatives

				c + d

		a + c	b + d

		all with occult	all without occult

		disease	disease


Gases	Training Set	Unlabeled Set	Test Set

Carbon monoxide	116	116	116

Toluene	132	132	132

Formaldehyde	253	253	253

All-3	501	501	501

Gases	Training Set	Unlabeled Set	Test Set

Formaldehyde	253	253	253

All-3	501	501	501


Boys

	Overall	Children	Adolescents	Normalweight	Overweight

Chocolate and snacks	23.2	20.5	25.3	22.5	25.1

Biscuits and					18.


Clinical features	Mean ± SD, n (%)

Age	66.5 ± 8.0

Weight	73.2 ± 8.5

Body mass index	27.8 ± 2.6

Gender

Male	12 (60)

Female	8 (40)

Smoking	9 (45)

Diseases

Hypertension	17 (85)

Heart failure	3 (15)

Diabetes	10 (50)

Medication

Organic nitrates	0 (0)

Aspirin	20 (100)

Beta-blockers	14 (70)

Angiotensin inhibitors	9 (45)

Calcium channel blockers	5 (25)

Hypolipidaemics	13 (65)

Clinical features	Mean ± SD, n (%)

Age	66.5 ± 8.0

W	73.

Clinical features	Mean ± SD, n (%)

eight	2 ± 8.5

Body mass index	27.8 ± 2.6

Gender

Male	12 (60)

Female	8 (40)

Smoking	9 (45)

Diseases

Hypertension	17 (85)

Heart failure	3 (15)

Diabetes	10 (50)

Medication

Organic nitrates	0 (0)

Aspirin	20 (100)

Beta-blockers	14 (70)

Angiotensin inhibitors	9 (45)

Calcium channel blockers	5 (25)

Hypolipidaemics	13 (65)


Cell type	Action	References

Langerhans cells	Activate and proliferate Treg cells in resting state; limit activation of Treg cells in presence of pathogen	[116]

Induce Treg cells favoring flora tolerance with limited antigens presentation	[117]

Induce Treg cells by secretion of IL-10 and TGF-β	[118]

Memory Treg cells	Localize to hair folliclesNon-migratory and non-responsive in normal skinProliferate and produce IL-17 in inflamed skin	[119]

Are activated, proliferated and differentiated into potent suppressorAttenuate autoimmune reactions in tissues upon repeated responses to antigens	[120]

Macrophages	Promote expression of the chemokine CCL22Induce migration and activation of Treg cells	[121]

Express M2-like TIM-4hiCD169+Act immunoregulatory function and promote engraftment of cardiac allografts	[122]

Mast cells	Act as intermediate at Treg cells dependent allograft tolerance via IL-9	[123]

Counteract Treg cell function through IL-6 and OX40/OX40L axis toward Th17 cell differentiation	[124]

Dermal dendritic cells	Are capable of antigen capture and presentation to CD4+ T cells and Treg cells generation	[125]

Dermal regulatory cells	Induce Treg cells through PD-1 engagement with expression of ABCB5+ molecules	[126]

Dermal fibroblasts	Induce proliferation of natural Treg cells with IL-15	[127]

Dermal stromal cells	Express CD90+ and induce Tregs cells	[128]

Cell type	Action	References

Dermal regulatory cells	Induce Treg cells through PD-1 engagement with expression of ABCB5+ molecules	[126]

Dermal fibroblasts	Induce proliferation of natural Treg cells with IL-15	[127]

Dermal stromal cells	Express CD90+ and induce Tregs cells	[128]


t-statistic and p-values for correlation significance

t-statistics

	Sig	NN

Sig

NN	2.917

NNSig	2.969	0.052

p-values

	Sig	NN

Sig

NN	0.998

NNSig	0.998	0.521


Age, sex, and education

Age

Mean ± std

Median

% of female patients

Level of education

% of none

% of primary (class I-V)

% of secondary + (class VI+)

No. of patients (N)


Generated Commands	Description

Start	SLAM and control algorithms begin

Stop	Stops robot's movements but the SLAM algorithm continues

Turn to the left	Sustained command to make the robot turning to user's left

Turn to the right	Sustained command to make the robot turning to user's right

Exit	SLAM stops and a map is visualized


Variable	Odds ratio (95% CI), P Value

Before accounting for confounding by indicationa	After accounting for confounding by indication

Methicillin-sensitive S. aureus carrier	0.5 (0.3, 1.0), 0.03	0.4 (0.2, 0.8), 0.01

Intubation	4.7 (1.8, 12.3), 0.002	5.3 (2.0, 14.4), 0.001

Fluoroquinolone	1.9 (1.2, 3.0), 0.01	-

Aminoglycoside	-	0.3 (0.1, 0.7), 0.003

Days from ICU admission to negative swab	< .0001	< .0001

1	1.0, reference	1.0, reference

2	2.0 (1.2, 3.3)	2.2 (1.3, 3.7)

≥ 3	15.6 (8.4, 29.0)	19.6 (10.4, 37.1)

Chronic liver disease	-	4.1 (1.2, 13.6), 0.02


 	Everolimus 1.5 mg (n = 61)	MMF 2 g (n = 61)

Recipient characteristics

Age (years)

 Mean ± standard deviation	42.5 ± 14.13	38.6 ± 11.36

 Median (range)	42.0 (18 to 65)	36.0 (20 to 64)

Gender, n (%)

 Male	46 (75.4)	37 (60.7)

 Female	15 (24.6)	24 (39.3)

Body mass index (kg/m2)

 Mean ± standard deviation	22.46 ± 4.03	21.79 ± 2.78

 Median (range)	21.97 (15.5 to 37.5)	21.09 (16.0 to 27.6)

Primary disease leading to transplantation, n (%)

 Glomerulonephritis/glomerular disease	16 (26.2)	9 (14.8)

 Polycystic disease	3 (4.9)	3 (4.9)

 Hypertension/nephrosclerosis	5 (8.2)	2 (3.3)

 Diabetes mellitus	3 (4.9)	5 (8.2)

 Interstitial nephritis	2 (3.3)	0 (0.0)

 Obstructive disorder/reflux	6 (9.8)	3 (4.9)

 IgA nephropathy	11 (18.0)	16 (26.2)

 Unknown	8 (13.1)	16 (26.2)

 Other	7 (11.5)	7 (11.5)

Current dialysis

 None	12 (19.7)	8 (13.1)

 Hemodialysis	42 (68.9)	48 (78.7)

 Peritoneal dialysis	7 (11.5)	5 (8.2)

HLA mismatches

 1	7 (11.5)	2 (3.3)

 2	9 (14.8)	16 (26.2)

 3	25 (41.0)	24 (39.3)

 <3	16 (26.2)	18 (29.5)

 ≥3	45 (73.8)	43 (70.5)

Donor characteristics

Mean ± standard deviation age (years)	52.3 ± 8.99	55.2 ± 8.23

Deceased heart beating, n (%)	1 (1.6)	0 (0.0)

Deceased nonheart beating, n (%)	0 (0.0)	1 (1.6)

Living related, n (%)	36 (59.0)	43 (70.5)

Living unrelated, n (%)	24 (39.3)	17 (27.9)

	Everolimus 1.5 mg (n = 61)	MMF 2 g (n = 61)

Deceased nonheart beating, n (%)	0 (0.0)	1 (1.6)

Living related, n (%)	36 (59.0)	43 (70.5)

Living unrelated, n (%)	24 (39.3)	17 (27.9)


Core/HP	Sample Depth	PCR-Product cp77444	PCR-Product cp103595	Cloning Success cp77444	Cloning Success cp103595	No. of Retrieved Sequences cp77444	Detected Variants cp77444	No. of Retrieved Sequences cp103595	Detected Variants cp103595

L14-02	7.53 m	+	+	+	-	0	-	-	-

-	EN2	-	-	n. c.	n.c.	-	-	-	-

L14-03	6.72 m	+	+	+	+	0	-	13	T

-	EN3	-	-	n.c.	n.c.	-	-	-	-

L14-03	7.59 m	+	-	+	n.c.	11	A	-	-

L14-03	8.56 m	+	+	+	+	8	A	7	3× C, 4× T

L14-03	9.61 m	-	-	n.c.	n.c.	-	-	-	-


Metabolite	Number of neighbors	P value

Reporter metabolites (up)

Glutathione [c]	10	6.0E-05

UDP-glucose [c]	11	3.1E-04

D-galactose [e]	6	2.5E-03

Alpha,alpha-trehalose 6-phosphate [c]	4	3.7E-03

Alpha,alpha-trehalose [c]	4	6.0E-03

Alpha-D-glucose 6-phosphate [c]	8	8.2E-03

Oxidized glutathione [c]	4	6.6E-03

CDP-diacylglycerol [m]	4	8.6E-03

Alpha-D-glucose [c]	23	2.2E-02

D-glucose 1-phosphate [c]	6	1.2E-02

Reporter metabolites (down)

AMP [c]	42	5.4E-09

ATP [c]	83	1.1E-08

5-phospho-alpha-D-ribose 1-diphosphate [c]	15	2.5E-06

L-glutamine [c]	17	6.6E-06

L-histidine [c]	7	8.2E-05

L-aspartate [c]	12	8.7E-05

CO2 [m]	10	1.3E-04

Isocitrate[m]	5	2.5E-04

Phosphate [c]	49	8.5E-05

Glycine [m]	4	9.6E-04


	No nGER (n = 42)	nGER (n = 48)	p-value

Exhaled air:

FeNO (ppb)	15 (13–20)	17 (11–25)	0.48

EBC:


Treatment	Belief	N	Recommendations	N	Adherence	N	Challenges to Adherence

Blood pressure	Believes blood pressure affects PKD	16	Prescribed blood pressure medication	16	Number of days per week when remember to take medication:		• Believes diet and exercise are better than drugs• Forgets when feeling well• Forgets when rushed, busy, or tired

<7 days/week	4

7 days/week	12

Exercise	Believes exercise or physical activity affects PKD	14	Told to avoid certain types of exercise or physical activity	11	Does not adhere to recommendations to avoid certain exercises of physical activity	2	• Activity helps mentally• Disagrees with recommendations (that exercise is harmful)

Diet	Believes diet affects PKD	16	Told to follow certain diets	15	Adherence to low-salt diet:		• Absence of or conflicting recommendations• Affects social aspects of eating• Difficult to measure

 • By non-physician sources	10	Does not add salt to food	12

Avoids salty food	4

Does not eat out/Cooks own meals	4

Water Intake	Believes drinking a lot of water affects PKD	10	Told to drink “a lot of water”	12	Adheres to recommendations	10	• Frequent urination• Experiences symptoms• Difficult to develop habit

 • By non-physician sources	3	Does not adhere to recommendations	1

Uncertain	5	Uncertain but tries to adhere to recommendations	5

Treatment	Belief	N	Recommendations	N	Adherence	N	Challenges to Adherence

Water Intake	Believes drinking a lot of water affects PKD	10	• By non-physician sources	3	Does not adhere to recommendations	1	• Frequent urination• Experiences symptoms• Difficult to develop habit

Uncertain	5	Uncertain but tries to adhere to recommendations	5


Metric	Questions	Average	Standard

		response	deviation

Overall usability	1–19	6.02	1.04

System usefulness	1–8	6.13	0.93

Information quality	9–15	5.66	1.20

Interface quality	16–18	6.24	0.99


Functional traits	Interpretation

Calvin–Benson cycle	CO2 fixation

Utilization of various carbon sources	Adaptation to the diverse organic matter in sponge mesohyl

Anaerobic respiration	Energy supply in anoxic environment

Denitrification	Energy supply in anoxic environment

Sulfate reduction	Energy supply in anoxic environment

Peptidase	Compensation for the reduced amino acid synthesis capacity

Endospore formation	Resistance to environmental threats; widespread distribution

Metal resistance	Resistance to environmental threats

Antibiotic resistance	Competition in symbiotic communities; resistance to environmental threats

Eukaryotic-like proteins	Host–microbe recognition

Type II secretion system	Interaction with host environment

Widespread Colonization Island	Tight adhesion

Type VI secretion system	Host–microbe interaction, microbe–microbe competition

Functional traits	Interpretation

Calvin–Benson cycle	CO2 fixation

Utilization of various c	Adaptation to the div

Functional traits	Interpretation

arbon sources	erse organic matter in sponge mesohyl

Anaerobic respiration	Energy supply in anoxic environment

Denitrification	Energy supply in anoxic environment

Sulfate reduction	Energy supply in anoxic environment

Peptidase	Compensation for the reduced amino acid synthesis capacity

Endospore formation	Resistance to environmental threats; widespread distribution

Metal resistance	Resistance to environmental threats

Antibiotic resistance	Competition in symbiotic communities; resistance to environmental threats

Eukaryotic-like proteins	Host–microbe recognition

Type II secretion system	Interaction with host environment

Widespread Colonization Island	Tight adhesion

Type VI secretion system	Host–microbe interaction, microbe–microbe competition


	Controls

Gender M:F	2:6

Age - median (range)	63.5 (56-78)

Smoking history (pack years)

Median (range)	50.0 (2-110)

FEV1 (% predicted)

Median (range)	88.0 (78-107)

FEV1/FVC - Median	101.5

DLCO (% predicted)

Median (range)	62.0 (34-122)


Procedures	References	Detergents	Detergent concentrations (C)	Ultrasound treatment (S)1)	Homogenization (H)2)	Filtration (F)

1	S.B. Singh-Verma (1968), LR. Bakken (1985)	Sodium hexametaphosphate	C1) 0,2% (w/v)	S1) 40 W, 60 sec, 5 impulses/sec (different repetitions)	H1) none	F1 none

 	 	C2) 0,5% (w/v)	S2) 65 W, 60 sec, 5 impulses/sec (different repetitions)	H2) 60 sec, speed 5 (different repetitions)	F2) 12–15 μm filter

2	S.B. Singh-Verma (1968), LR. Bakken (1985)	Bromhexine hydrochloride	C1) 0,2% (w/v)	S1) 40 W, 60 sec + 65 W, 60 sec, 5 impulses/sec	H1) none	n.a.

 	 	 	 	H2) 2× 60 sec, speed 5

3	W.B. Yoon and R.A. Rosson (1990)	Tween	C1) 5 μg/ml	S1) 15 W, 30 sec, 5 impulses/sec	H1) none	n.a.

 	 	C2) 10 μg/ml	S2) 35 W, 30 sec, 5 impulses/sec	H2) 5 min, speed 5

 	 	C3) 25 μg/ml

4	E.L Schmidt (1974)	Tween 80 + 0.007 g ml-1 flocculation reagent (Ca (OH)2: MgCO3 (2:5))	C1) 25 μl/ml	n.a.	n.a.	n.a.

5	O. Resina-Pelfort et al. (2003)	Triton X-100	C1) 10 μg/ml	S1) 35 W, 30 sec, 5 impulses/sec	H1) none	n.a.

 	 	C2) 20 μg/ml	S2) 45 W, 30 sec, 5 impulses/sec	H2) 5 min, speed 5

6	L R. Bakken (1985)	Sodium pyrophosphate	C1) 0,2% (w/v)	S1 3× 40 W, 60 sec, 5 impulses/sec	H1) 3× 60 sec, speed 5	n.a.

Procedures	References	Detergents	Detergent concentrations (C)	Ultrasound treatment (S)1)	Homogenization (H)2)	Filtration (F)

6	L R. Bakken (1985)	Sodium pyrophosphate	C1) 0,2% (w/v)	S1 3× 40 W, 60 sec, 5 impulses/sec	H1) 3× 60 sec, speed 5	n.a.


Programme, Country	Water Frequency 1	Fruit Juices Frequency 2	Soft Drinks Frequency 2

VIASANO, Belgium	4 (4–5)	6 (4–6)	4 (2–5)

Healthy kids in Bulgaria, Bulgaria	6 (5–6)	4 (3–5)	2 (1–4)

EPODE Flandre Lys, France	4 (4–5)	6 (4–6)	3 (2–5)

Paideiatrofi, Greece	5 (5–6)	4 (4–5)	1 (1–2)

MAIA, Portugal	5 (4–6)	4 (2–4)	2 (1–3)

SETS, Romania	5 (5–6)	4 (3–5)	2 (2–4)

JOGG Zwolle, The Netherlands	4 (3–4)	3 (2–5)	3 (2–6)

Total	5 (4–6)	4 (3–6)	2 (1–4)

Programme, Country	Water Frequency 1

VIASANO, Belgium	4 (4–5)

Healthy kids in Bulgaria, Bulgaria	6 (5–6)

EPODE Flandre Lys, France	4 (4–5)

Paideiatrofi, Greece	5 (5–6)

MAIA, Portugal	5 (4–6)

SETS, Romania	5 (5–6)

JOGG Zwolle, The Netherlands	4 (3–4)

Total	5 (4–6)


Authors 	Results

Gavini et al. [25]	Ion-implanted instruments reached significantly higher cycle numbers before fracture compared to annealed and non-implanted files.

Wolle et al. [26]	Argon II improved the performance of S1 files moderately, whereas nitrogen ion-implanted files performed worse in the fatigue test.

ors	s

Gavini et al. [25]	Ion-implanted instruments reached significantly higher cycle numbers before fracture compared to annealed and non-implanted files.

Wolle et al. [26]	Argon II improved the performance of S1 files moderately, whereas nitrogen ion-implanted files performed worse in the fatigue test.


Cause of corneal opacification	Eyes

Posttrauma	25

Postcorneal ulcer	20

Glaucoma	4

Unknown	4

Cause of corneal opacification	Eyes

Posttr	2

Cause of corneal opacification	Eyes

auma	5

Postcorneal ulcer	20

Glaucoma	4

Unknown	4


GenBank accession no.	Original name	Country

HQ591366	PCV2 , isolate 90-08-21	Croatia, 2008

HQ591367	PCV2, isolate 110-08-2	Croatia, 2008

AY256460	PCV2, strain 375	Hungary, 2003

AY424405	PCV2, isolate AUT5	Austria, 2003

HQ591368	PCV2, isolate 126-07-5	Croatia, 2007

HQ591369	PCV2, isolate 147-07-7	Croatia, 2007

HQ591370	PCV2, isolate 161-08-2	Croatia, 2008

HQ591365	PCV2, isolate 70-08-2	Croatia, 2008

AY180397	PCV2, strain Pingtung-5	Taiwan, 2002

AY484410	PCV2, isolate NL-control-4	Netherlands, 2003

AF311296	BFDV	Australia, 2000

AF071879	PCV1	SAD, 1998

GU930366	PRRSV, isolate Hun06	Hungary, 2009

AY035960	PRRSV, isolate 361-4	Denmark, 1994

JQ043210	PRRSV, 174-07-1	Croatia, 2007

DQ324711	PRRSV, isolate Prz-87	Poland, 2005

JQ043212	PRRSV, isolate 660-07-2	Croatia, 2007

JQ043213	PRRSV, isolate 1152-08-10	Croatia, 2008

AY035976	PRRSV, strain 2567/96	Italy, 1996

AY035961	PRRSV, isolate 48/92-1	Denmark, 2001

AY035975	PRRSV, isolate 2481/97	Denmark, 2001

M96262	Lelystad virus	Netherlands, 1991

JQ043211	PRRSV, 177-07-2-1	Croatia, 2007

GU930368	PRRSV, isolate Hun08	Hungary, 2009

DQ324708	PRRSV, strain Okt-46	Belarus, 2004

DQ324719	PRRSV, strain Soz-6	Belarus, 2004

DQ324727	PRRSV, strain Yuz-34	Belarus, 2004

EU071271	PRRSV, strain KR	Russia, 2007

AF438362	PRRSV, strain Aus	Lithuania, 2000

DQ324701	PRRSV, strain Bor-41	Belarus, 2004

DQ324702	PRRSV, strain Bor-54	Belarus, 2004

L39363	PRRSV, isolate IL1	United States, 1996

L39362	PRRSV, isolate IA6	United States, 1996

U18750	PRRSV, isolate ISU-3927	United States, 1996

GenBank accession no.	Original name	Country

DQ324701	PRRSV, strain Bor-41	Belarus, 2004

DQ324702	PRRSV, strain Bor-54	Belarus, 2004

L39363	PRRSV, isolate IL1	United States, 1996

L39362	PRRSV, isolate IA6	United States, 1996

U18750	PRRSV, isolate ISU-3927	United States, 1996


	Total	Men	Women

Descriptor	Cases/total study group, n	ID (95% CI)c	Cases/total study group, n	ID (95% CI)c	Cases/total study group, n	ID (95% CI)c


Variable	No. patients (n = 41)*	Median expression Survivin DeltaEx3	AD	p

FIGO stage

IB	0 (8)	0	0	0.59

IIB	2 (16)	0.09	24.51

IIIB	2 (17)	0.11	35.68

Histology of tumors

Squamous cell	2 (34)	0.01	16.99	0.04

Adenocarcinoma	2 (5)	0.22	60.12

Adenosquamous	0 (2)	0	0

Menopause

Pre-Menopause	2 (10)	0.14	48.94	0.33

Menopause	1 (8)	0.02	10.65

Post-Menopause	1 (23)	0.01	14.99

Variable	No. patients (n = 41)*	Median expression Survivin DeltaEx3	AD	p

Menopause

Pre-Menopause	2 (10)	0.14	48.94	0.33

Menopause	1 (8)	0.02	10.65

Post-Menopause	1 (23)	0.01	14.99


	Independent association with increasing RANKL expression (Pvalue)	Independent association with increasing RANK expression (Pvalue)

Diagnosis during pregnancy (yes vs. no)	<0.001	0.67

Tumor size (≤2 cm vs. >2 cm)	0.23	0.87

Nodal involvement (negative vs. positive)	0.15	0.19

Histological grade (I vs. II vs. III)	0.09	0.7

Breast cancer subtypes (luminal A vs. luminal B vs. HER2 vs. triple negative)	0.75	<0.001

Increasing progesterone receptor expression by IHC (continuous variable)	<0.001	0.17

Neoadjuvant chemotherapy (yes vs. no)	0.69	<0.001


Variable	Admission Serum Chloride (Cl0)≥110 mEq/L(n = 303)	Admission Serum Chloride (Cl0)101–109 mEq/L(n = 561)	Admission Serum Chloride (Cl0)≤100 mEq/L(n = 181)	P-value


Overall ranking scale (on a scale from 1–10)

Question: In the last two days of care, how well did the doctors, nurses and other professional staff...	Average

Provide medical care that respected his/her wishes?	8.2

Make sure that [patient] died with dignity – that is died on her/his own terms?	8.2

Make sure [patient’s] symptoms were controlled to a degree acceptable to her/him?	8

Communicate with patient and family about the illness and likely outcomes of care?	7.3

Provide emotional support for you and [patient’s] family and friends?	6.8

What number would you give the overall care that [patient] received in the last two days of life?	7.7

Scale score	7.7

Comparison of Domain Scores (range: 0 to 1)

Advance care planning	0.10

Coordination	0.16

Focus on individual	0.271

Informing & decision making	0.301

Attend to family	0.511

Overall ranking scale (on a scale from 1–10)

Question: In the last two days of care, how well did the doctors, nurses and other professional staff...	Average

Advance care planning	0.10

Coordination	0.16

Focus on individual	0.271

Informing & decision making	0.301

Attend to family	0.511


	General CVRM networks	Specific CVRM networks

Mean	SD	Min	Max	Mean	SD	Min	Max

Density	0.38	0.17	0.08	0.83	0.37	0.22	0	0.83

Number of high frequency contacts	8.87	5.64	0	20	10.65	8.24	0	33

Centrality of CVRM coordinator	6.61	3.38	2.00	16	7.07	4.97	0	24

Homophily on SBP targets	0.60	0.43	−0.42	1.00	0.55	0.46	−0.46	1.00

Homophily on LDL targets	0.53	0.49	−0.87	1.00	0.52	0.52	−0.87	1.00


	Healthy population	Clinic populationa	Pairwise comparisons

	BV = 0	BV = 0	BV = 1	HP vs. CPBVneg	HP vs. CPBVpos	CPBVneg vs. CPBVpos

	N = 30	N = 29	N = 12

	N (%)	N (%)	N (%)	p-value	p-value	p-value

L. crispatus	23 (77)	23 (79)	5 (42)	1.000	0.067	0.029


Age, years

Mean ± SD	40.3 ± 11.3	39.3 ± 11.3

Median	40	34

Range	20–60	26–60


Partner Medicines	Below 85 %	Within 85–115 %	Above 115 %	Total N = 254


Code	Alkali Treatment	Silane Coupling Agent	Volume Fraction of Fiber Vf (vol %)

PA1010	-	-	-

HF	-	-	20

HF-S1	NaOH	S1 (Aminosilane)	20

HF-S2	NaOH	S2 (Epoxysilane)	20

HF-S3	NaOH	S3 (Ureidosilane)	10, 20, 30


Purification step	Total fused peptide (mg)	Total p53pAnt (mg)	Purity (%)	Yield (%)

Total protein extract	n.d	n.d	43*	100

Inclusion bodies	n.d	n.d	79*	-

First affinity chromatography	184**	43	90*	-

Precipitation recovery	184	43	-	100*

Thrombin cleavage	-	-	-	95*

Second affinity chromatography	-	34**	95	85*

Purification step	Total fused peptide (mg)	Total p53pAnt (mg)	Purity (%)

Total protein extract	n.d	n.d	43*

Inclusion bodies	n.d	n.d	79*

First affinity chromatography	184**	43	90*

Precipitation recovery	184	43	-

Thrombin cleavage	-	-	-

Second affinity chromatography	-	34**	95


Variables	Chlorhexidine	Placebo	Dry cord

Hospital data	(n = 86)	(n = 86)	(n = 75)

 Age of mother (years, mean ± SD)	23.87 ± 2.54	23.77 ± 2.86	25.12 ± 3.24

 Vaginal delivery	100.0	100.0	100.0

 Male births	48.8	64.0	58.7

 Birth weight (grams, mean ± SD)	2728.3 ± 479.5	2684.3 ± 453.6	2794.8 ± 437.6

 No. of pelvic examinations (mean ± SD)	2.37 ± 1.25	2.07 ± 1.00	2.00 ± 0.97

Problems during delivery

 Meconium staining	2.3	2.3	5.3

 Prolonged labor	2.3	1.2	1.3

Maternal risk factors for infection

 LPVb > 24 h	4.7	2.3	2.7

Chorioamnionitis	0.0	0.0	0.0

 Fever in mother	1.2	0	1.3

 Maternal UTI	0.0	0.0	1.3

Time since birth (hrs:min, mean ± SD)	4:39 ± 2.31	4:35 ± 2:49	4:12 ± 2:37

Community data	(n = 36)	(n = 24)	(n = 19)

Age of mother (years, mean ± SD)	24.42 ± 3.95	24.62 ± 4.13	25.79 ± 3.91

Male births	38.9	50.0	52.6

Did the person clean hands before conducting delivery	97.2	100.0	100.0

New razor blade for cutting the cord	100.0	95.8	100.0

Baby given bath immediately after delivery	94.4	100.0	100.0

Variables	Chlorhexidine	Placebo	Dry cord

New razor blade for cutting the cord	100.0	95.8	100.0

Baby given bath immediately after delivery	94.4	100.0	100.0


Characteristics	Frequency n = 82	Percent (%)

<underline>Age</underline>(years)	Mean Age =27.6, SD =4.5

16–20	6	7.3

21–25	22	26.8

26–30	37	45.1

31–35	12	14.6

36-40	5	6.1

<underline>Marital Status</underline>

Married	76	92.7

Single	1	1.2

Cohabiting	2	2.4

No response	3	3.7

<underline>Occupation</underline>

Employed	16	19.5

Student	8	9.8

Civil servant	2	2.4

Unemployed	8	9.8

Artisan	14	17.1

Trading	32	39

No response	2	2.4

<underline>Educational attainment</underline>

Primary	9	10.9

JSS	21	25.6

SSS	11	13.4

Poly technique	21	25.6

University	15	18.3

No response	5	6.1

<underline>Religion</underline>

Christianity

Islam	34

48	41.5

58.5

<underline>Ethnic group</underline>

Yoruba	72	87.8

Igbo	6	7.3

No response	4	4.8

Characteristics	Frequency n = 82	Percent (%)

Age(years)	Mean Age =27.6, SD =4.5

16–20	6	7.3

21–25	22	26.8

26–30	37	45.1

31–35	12	14.6

36-40	5	6.1

Marital Status

Married	76	92.7

Single	1	1.2

Cohabiting	2	2.4

No response	3	3.7

Occupation

Employed	16	19.5

Student	8	9.8

Civil servant	2	2.4

Unemployed	8	9.8

Artisan	14	17.1

Trading	32	39

No response	2	2.4

Characteristics	Frequency n = 82	Percent (%)

Educational attainment

Primary	9	10.9

JSS	21	25.6

SSS	11	13.4

Poly technique	21	25.6

University	15	18.3

No response	5	6.1

Religion

Christianity

Islam	34

48	41.5

58.5

Ethnic group

Yoruba	72	87.8

Igbo	6	7.3

No response	4	4.8


miR ID	Present result	Previous report	Type of sample	Reference

hsa-miR-106b-5p	↑	↓	Brain	[13]

hsa-miR-181b-5p	↓	↓	Brain, lymphoblastoid cell line	[13,16]

hsa-miR-195-5p	↑	↑	Lymphoblastoid cell line	[15]

hsa-miR-19b-3p	↑	↓	Lymphoblastoid cell line	[14]

hsa-miR-320a	↓	↓	Lymphoblastoid cell line	[14]

hsa-miR-328	↓	↓	Brain	[13]

hsa-miR-663a	↓	↑	Lymphoblastoid cell line	[14]


	Accuracy (%)	Sensitivity (%)	Specificity (%)	Auc (%)

FEATURE 1	95.00	87.50	96.87	—

FEATURE 2	87.80	100.00	84.84	—


Cell Line	Tumor Type	NOTCH1 Mutation	Effect on NOTCH1 Signaling	Reference

KOPT-K1	T-LL	L1600P/del(P)*	Gain	 [3]

REC-1	MCL	del(ECN1)/del(P)*	Gain	this paper/ [7]

MAVER-1	MCL	None	N.A.	 [7]

HCC1599	Breast Carcinoma	del(ECN1)	Gain	 [10]

MB-157	Breast Carcinoma	del(ECN1)	Gain	Unpublished data

HCC1587	Breast Carcinoma	None	N.A.	 [10]

Cell Line	Tumor Type	NOTCH1 Mutation	Effect on NOTCH1 Signaling	Reference

KOPT-K1	T-LL	L1600P/del(P)*	Gain	[3]

R	MC	d	Gain	this pape

EC-1	L	el(ECN1)/del(P)*		r/ [7]

MAVER-1	MCL	None	N.A.	[7]

HCC1599	Breast Carcinoma	del(ECN1)	Gain	[10]

MB-157	Breast Carcinoma	del(ECN1)	Gain	Unpublished data

HCC1587	Breast Carcinoma	None	N.A.	[10]


Assessment1	Telehone interview	Baseline visit	3 month visit	6 month visit	12 month visit	24 month visit

AD patient

Inclusion criteria	X

Demographics, diagnoses, drugs		X

CDR		X				X

MMSE		X			X	X

Verbal flow, clock drawing test		X	X	X	X	X

MNA		X

Weight, BMI		X	X	X	X	X

Mobility and balance tests by Guralnik		X	X	X	X	X

FIM		X	X	X	X	X

NPI		X		X

Grip strength, blood pressure, heart rate		X	X	X	X	X

Cornell depression scale		X			X

Falls and fractures			X	X	X	X

Use of health and social services, admission to permanent institutional care, mortality			X	X	X	X

Spousal caregiver

Demographics, diagnoses, drugs		X

Zarit burden scale		X			X	X

GDS		X			X

RAND-36 QOL		X			X	X

Mobility and balance tests by Guralnik		X			X

Use of health and social services, mortality			X	X	X	X


Gender	Age	Age at onset	Evidence for a diagnosis of epilepsy	MRI

EEG	Other features	Treatment response

M	70	66	Non-specific bilateral temporal lobe slowing	Oroalimentary automatisms, gustatory hallucinations	Complete	Normal

M	62	54	L temporal epileptiform	Oroalimentary automatisms	Complete	Normal

M	68	65	Non-specific L temporal slowing	No	Complete	Normal

M	72	71	Non-specific R temporal slowing	Déjà vu	Complete	Bilateral high T2 signal in hippocampus

M	68	62	Bilateral (L more marked) mid-anterior temporal sharp and slow-wave epileptiform	Oroalimentary automatisms; brief unresponsiveness	Complete	Normal

M	76	65	Non-specific bilateral temporal slowing	Olfactory hallucinations	Complete	Normal

M	66	56	Normal	Olfactory hallucinations; brief unresponsiveness	Complete	Normal

M	64	61	Bilateral temporal epileptiform	Olfactory hallucinations; oroalimentary automatisms	Complete	Normal

M	63	59	Normal	No	Complete	Normal

M	76	73	Normal	Oroalimentary automatisms; brief unresponsiveness	Complete	Normal

F	60	55	Non-specific bilateral temporal slowing	Brief unresponsiveness	Complete	Normal

Gender	Age	Age at onset	Evidence for a diagnosis of epilepsy	MRI

EEG	Other features	Treatment response

F	60	55	Non-specific bilateral temporal slowing	Brief unresponsiveness	Complete	Normal


level of convergence	phenotype	organism	references

nucleotide

coding mutations in several genes	rate of proliferation in a novel host and at higher temperature	X174 virus	[21]

Gly119Ser in ace-1	organophosphate resistance	seven insect species	[22,23]

gene

pykF and nadR	rate of proliferation in a glucose-limited medium	Escherichia coli	[24]

yellow	wing spot	Drosophila tristis and Drosophila biarmipes	[25]

protein accumulation profile

proteins regulated by guanosine tetraphosphate	rate of proliferation in a glucose-limited medium	E. coli	[26]

molecular pathway

RNA polymerase complex	rate of proliferation at high temperature	E. coli	[14]

organ

compound eye	sensitivity to light	certain annelids, arrow worms, insects	[7]

behaviour and organs

no sound production and flat wings	no sound production, protection against parasitoids	criquets	[27]

feeding behaviour and habitat adaptations	ecology and body morphology	lizards	[28]


Maize gene	Intron TE insertion(s)	Maize gene length (Kb)	Sorghum ortholog gene length (Kb)

ZmTti1	2 Kb hobo DNA transposon	20.87	12.1

ZmTti2	6 Kb Gypsy LTR retrotransposon	9.1	4.2

ZmATM	2.2 Kb L1/CIN4 retrotransposon	131	71

	2.1 Kb L1/CIN4 retrotransposon

	1.7 Kb L1/CIN4 retrotransposon

	3.1 Kb Ty1/Copia retrotransposon

	1.2 Kb Ty1/Copia retrotransposon

ZmATR	2.4 Kb Gypsy LTR retrotransposon	45	31

	10.2 Kb Gypsy LTR retrotransposon

	3 Kb Ty1/Copia retrotransposon

	4.7 Kb Ty1/Copia retrotransposon

ZmSMG1	1.4 Kb Ty1/Copia retrotransposon	30	22.6

	2.1 Kb L1/CIN4 retrotransposon

ZmTOR	2 Kb L1/CIN4 retrotransposon	51	31.8

	5 Kb Ty1/Copia retrotransposon


Paternal MHC class I Haplotypea	Non-BNP calves (n = 21)	BNP calves (n = 9)	P-valueb	FDR-derived significance thresholdsc

A19variants	2	0	1.000	0.039

A20variant	1	0	1.000	0.043

H2	1	0	1.000	0.046

H5v2(UU)	2	0	1.000	0.050


ICD-10 Code	# of patients	Prescribed Antibiotic	Cases that needed antibiotic	Cases that needed + received antibiotics	Appropriate prescription rate (%)	Adequate prescription rate (%)

J00	581	17	14	1	82.36	7.14

J01	93	70	4	4	5.71	100

J02	306	157	9	5	3.18	2.94

J03	166	138	16	15	11.59	93.75

J04	34	12	0	0	–	–

J05	8	0	0	0	–	–

J06	191	117	0	0	0	0

J10	0	0	0	0	–	–

J11	0	0	0	0	–	–

H65	8	6	2	2	33.33	100

H66	6	6	6	6	100	100

Total	1393	523	51	33	9.75	64.70


G grade	Number of tumor samples

CD146 expression

Low/absent	incomplete high	complete high

1		3

2	4	3	12

3	2	9	7

4			1

total	6	15	20


	Base model	Effect modification model

OR	95%CI	OR	95%CI

SNAP participation (ref = eligible non-participants)	2.02	1.44-2.83	2.09	1.48-2.95

Age (years)	1.02	1.01-1.03	1.02	1.01-1.03

Gender (ref = female)	0.45	0.30-0.67	0.45	0.30-0.67

Race/ethnicity (ref = Non-Hispanic white)

 Non-Hispanic black	2.79	1.45-5.38	2.76	1.43-5.32

 Hispanic	2.15	1.30-3.56	2.12	1.28-3.51

 Other	1.46	0.64-3.35	1.42	0.62-3.26

Marital status (ref = married)

 Cohabitating, not married	1.12	0.70-1.81	1.11	0.69-1.79

 Single	0.94	0.67-1.32	0.93	0.66-1.31

Working status (ref = yes)	0.96	0.70-1.32	0.95	0.69-1.32

Mental health (ref = not having a mental health problem)	1.53	0.93-2.50	1.54	0.94-2.52

Neighborhood poverty category (ref = not poor)

 Poor	1.18	0.78-1.80	1.16	0.76-1.77

 Very poor	1.02	0.67-1.57	1.01	0.66-1.55

Density unhealthy food outlets	1.01	0.98-1.03	1.00	0.97-1.03

SNAP participation* Density unhealthy food outlets			1.02	0.99-1.05


RADIODENCITY OF BONE GRAFTS	At 7th day follow-up	At 1st month follow-up	At 6 months follow-up	At 1 year follow-up

	No. of pts.	%	No. of pts.	%	No. of pts.	%	No. of pts.	%

GOOD	178	100	171	96.1	162	91.0	147	82.6

PARTIAL	00	00	03	1.7	09	5.1	17	9.5

LUCENT	00	00	04	2.2	07	3.9	14	7.9

Total	178	100.0	178	100.0	178	100.0	178	100


	1st visitFebruary 2012	2nd visitApril 2012	Last visit before starting dialysis June 2014

Weight (kg)	84,3	82,9	76

BMI (kg/m2)	29	28	25

eGFR (mL/min/1,73 m2)	19	16	12

P-Urea (mmol/L)	28,8	18,3	24,4

P-Creatinine (μmol/L)	389	401	777

P-Phosphate (mmol/L)	1,3	1,3	1,4

P-Potassium (mmol/L)	3,6	3,8	4,0

P-Albumin (g/L)	38	39	38

Pt(U)-Urea (mmol/d)		205 = 47 g protein	162 = 40 g protein

	1st visitFebruary 2012	2nd visitApril 2012

Weight (kg)	84,3	82,9

BMI (kg/m2)	29	28

eGFR (mL/min/1,73 m2)	19	16

P-Urea (mmol/L)	28,8	18,3

P-Creatinine (μmol/L)	389	401

P-Phosphate (mmol/L)	1,3	1,3

P-Potassium (mmol/L)	3,6	3,8

P-Albumin (g/L)	38	39

Pt(U)-Urea (mmol/d)		205 = 47 g protein

Last visit before starting dialysis June 2014

76

25

12

24,4

777

1,4

4,0

38

162 = 40 g protein


Subject number	Region of interest	H&E staining	APP staining

Sheep 01	AL	Normal	0

AR	Normal	1

BL	Normal	0

BR	Microglial activation	2

C	Focal hemorrhagic necrosis	2

D	Normal	0

Sheep 03	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Normal	0

C	Normal	0

D	Small perivascular petechial hemorrhage	1

Sheep 04	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Small perivascular petechial hemorrhage at edge, artifact?	0

C	Small perivascular petechial hemorrhage at edge, artifact?	0

D	Normal	0

Sheep 05	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Normal	0.5

C	Normal	0

D	Normal	0

Sheep 06	AL	Localized focus of acute meningitis and SAH in depth of sulcus	0

AR	Normal	0

BL	Normal	0

BR	Normal	0

C	Focal hemorrhage near deep gray nuclei	2

D	Normal	0

Sheep 07	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Normal	0

C	Normal	0

D	Normal	0

Subject number	Region of interest	H&E staining	APP staining

Sheep 06	D	Normal	0

Sheep 07	AL	Normal	0

AR	Normal	0

BL	Normal	0

BR	Normal	0

C	Normal	0

D	Normal	0


Recipient	No. of embryos transferred	No. offetuses	Days of gestation	Fetal fibroblast cell lines	Mono-allelic cell lines (%)	Bi-allelic cell lines (%)

R725	205	6	26	F1, F2, F3, F4, F5, F6	F3, F4, F5(50.0)	F1, F2(33.3)

R801	181	2	29	F7, F8	-(0%)	-(0%)


SVMs Models With Different Input Variable	Mean Absolute Percentage Error (MAPE) (%)

(a) Rebound Hammer (RH) Test	8.92%

(b) Ultrasonic Pulse Velocity (UPV) Test	9.25%

(c) SonReb (RH+UPV) Test	6.77%


Province	Area (Hectares)	National Percentage	Province	Area (Hectares)	National Percentage

Agusan del Norte	244.98	0.1	Leyte	5,807.07	2.26

Aklan	1,144.44	0.45	Maguindanao	907.92	0.35

Albay	1,081.17	0.42	Marinduque	2,732.22	1.06

Antique	945.9	0.37	Masbate	5,302.08	2.06

Aurora	497.07	0.19	Metropolitan Manila	39.69	0.02

Basilan	7,641.18	2.97	Misamis Occidental	2,066.49	0.8

Bataan	238.59	0.09	Misamis Oriental	341.19	0.13

Batangas	508.95	0.2	Negros Occidental	4,393.26	1.71

Biliran	231.39	0.09	Negros Oriental	2,004.93	0.78

Bohol	9490.5	3.69	Northern Samar	4,286.52	1.67

Bulacan	391.14	0.15	Occidental Mindoro	1,842.93	0.72

Cagayan	5,175.27	2.01	Oriental Mindoro	2,975.31	1.16

Camarines Norte	3,628.17	1.41	Palawan	5,6261.3	22.23

Camarines Sur	5,315.31	2.07	Pampanga	251.73	0.1

Camiguin	4.95	0	Pangasinan	1,206.63	0.47

Capiz	1,999.8	0.78	Quezon	14,170	5.51

Catanduanes	1,671.3	0.65	Romblon	792.45	0.31

Cavite	35.73	0.01	Samar	10,140.6	3.94

Cebu	2,893.77	1.13	Sarangani	92.61	0.04

Compostela Valley	130.14	0.05	Shariff Kabunsuan	1,018.89	0.4

Davao del Norte	195.57	0.08	Siquijor	70.2	0.03

Davao del Sur	361.53	0.14	Sorsogon	3,895.74	1.52

Davao Oriental	1975.5	0.77	South Cotabato	13.86	0.01

Dinagat Islands	1654.56	0.64	Southern Leyte	643.68	0.25

Eastern Samar	5,595.93	2.18	Sultan Kudarat	949.95	0.37

Guimaras	577.08	0.22	Sulu	2,0564.8	8

Ilocos Norte	127.53	0.05	Surigao del Norte	11867	4.62

Ilocos Sur	228.87	0.09	Surigao del Sur	5,642.55	2.19

Iloilo	1,322.91	0.51	Tawi-Tawi	11,322.2	4.4

Isabela	592.29	0.23	Zambales	981.54	0.38

La Union	144.18	0.06	Zamboanga del Norte	1,961.82	0.76

Lanao del Norte	1,580.94	0.61	Zamboanga del Sur	9,501.66	3.7

Lanao del Sur	620.37	0.24	Zamboanga Sibugay	13,889.2	5.4

Province

Agusan del Norte

Aklan

Albay

Antique

Aurora

Basilan

Bataan

Batangas

Biliran

Bohol

Bulacan

Cagayan

Camarines Norte

Camarines Sur

Camiguin

Capiz

Catanduanes

Cavite

Cebu

Compostela Valley

Davao del Norte

Davao del Sur

Davao Oriental

Dinagat Islands

Eastern Samar

Guimaras

Ilocos Norte

Ilocos Sur

Iloilo

Isabela

La Union

Lanao del Norte

Lanao del Sur


Marker	D number	Primer sequences (5’>3’)	Annealing temperature (°C)	Product size (bp)

ATA29H01 	D12S1048	GGTCTGCTTAGGTCCCTTTT 	55	209-229

 	 	AAGGAACCAAGGAGTGGAAG

Mfd75A 	D12S59	CTCACTCATGCTTGTTTTGA 	60.3	164-179

 	 	GATCACGTCAGACTGGGCT

AFM092wd11 	D12S331	TAACATTTATTCATCTCCATACTGA 	57.8	175-181

 	 	ACATGTAAGAGAGNAAGTTTACAAA

AFM296yg5 	D12S345	CAGCCTGGGTAACAAA 	57.8	209-238

 	 	AGCAATGTGTGCATTC

UT8102 	D16S689	GCCTGGGCGATAAGTGAGA 	56	209

 	 	TCACCACAACCCAAACATTC

AFM156xb8 	D16S3026	CTCCCTGAGCAACAAACACC 	55	178-210

 	 	GGTCATTTATATGCGCCTGA

AFMa306yf1 	D16S3063	AGCTTGTTTTAGCAANAATTTC 	59	218-260

 	 	TGCCTGATTCCACCAA

AFM342xd9	D16S3121	CATGTTGTACATCGTGATGC 	58	79-85

 	 	AGCTTTTATTTCCCAGGGGT

Primer sequences (5’>3’)	Annealing temperature (°C)	Product size (bp)

GGTCTGCTTAGGTCCCTTTT	55	209-229

AAGGAACCAAGGAGTGGAAG

CTCACTCATGCTTGTTTTGA	60.3	164-179

GATCACGTCAGACTGGGCT

TAACATTTATTCATCTCCATACTGA	57.8	175-181

ACATGTAAGAGAGNAAGTTTACAAA

CAGCCTGGGTAACAAA	57.8	209-238

AGCAATGTGTGCATTC

GCCTGGGCGATAAGTGAGA	56	209

TCACCACAACCCAAACATTC

CTCCCTGAGCAACAAACACC	55	178-210

GGTCATTTATATGCGCCTGA

AGCTTGTTTTAGCAANAATTTC	59	218-260

TGCCTGATTCCACCAA

CATGTTGTACATCGTGATGC	58	79-85

AGCTTTTATTTCCCAGGGGT


Gene	Forward	Reverse

EP1	5′-ATGGTGGGCCAGCTTGTC-3′	5′-GCCACCAACACCAGCATTG-3′

EP2	5′-TCCTTGCCTTTCACGATTT-3′	5′-AGAGCTTGGAGGTCCCATT-3′

EP3	5′-TGGTCTCCGCTCCTGATAA-3′	5′-TGCATTCTTTCTGCTTCTCC-3′

EP4	5′-TGCTCTTCTTCAGCCTGTCC-3′	5′-GAGCTACCGAGACCCATGTT-3′

FP	5′-TCTGGTCTGTGCCCACTTC-3′	5′-GACTCCAATACACCGCTCAAT-3′

PGT	5′-CTGGTGGATTTCATTAAACGG-3′	5′-GGCTGCTGAGGTGCCATAC-3′

MRP4 total	5′-AAAGTGCCAAAGTAATCCAGC-3′	5′-GTTCAAAGCCACAGAATCCA-3′

MRP4 variant 1	5′-CGGGCATACAAAGCAGAA-3′	5′-GGACCCAAAGGCAACG-3′


Body Areas	Severity of Hirsutism	p

Mild	Moderate	Severe

Mean	SE *	Mean	SE	Mean	SE

Upper lip	1.99	0.07	2.60	0.07	3.10	0.22	<0.001

Chin	2.07	0.11	3.16	0.10	3.95	0.05	<0.001


Technique	Comments

PRECONTRAST

Dark blood stacks typically in axial, coronal and sagittal planes e.g. HASTE	Provides vessel wall imaging as well as complementary information to CE-MRA regarding lumen

Noncontrast bright blood stack(s) e.g. SSFP

 	CONTRAST

3D contrast-enhanced magnetic resonance angiography e.g. spoiled gradient echo	Appropriate vasculature should be covered depending on clinical questions and known or suspected diagnosis (see Table 2)

 	POSTCONTRAST

T1-weighted vessel wall imaging e.g. VIBE or FAME	Additional vessel wall imaging, particularly useful to delineate thickening and thrombus

 	CARDIAC ACQUISITIONS

Multiplane cine imaging e.g. SSFP Aortic valve velocity-encoded cine Myocardial imaging: T2 precontrast, T1W early post contrast, late post-gadolinium imaging	May be appropriate when aortic root disease involves the aortic valve or when myocardial inflammation is suspected, particularly in small-vessel vasculitides

Technique	Comments

PRECONTRAST

D	Provides vessel wa

Technique	Comments

ark blood stacks typically in axial, coronal and sagittal planes e.g. HASTE	ll imaging as well as complementary information to CE-MRA regarding lumen

Noncontrast bright blood stack(s) e.g. SSFP

	CONTRAST

3D contrast-enhanced magnetic resonance angiography e.g. spoiled gradient echo	Appropriate vasculature should be covered depending on clinical questions and known or suspected diagnosis (see Table 2)

	POSTCONTRAST

T1-weighted vessel wall imaging e.g. VIBE or FAME	Additional vessel wall imaging, particularly useful to delineate thickening and thrombus

	CARDIAC ACQUISITIONS

Multiplane cine imaging e.g. SSFP Aortic valve velocity-encoded cine Myocardial imaging: T2 precontrast, T1W early post contrast, late post-gadolinium imaging	May be appropriate when aortic root disease involves the aortic valve or when myocardial inflammation is suspected, particularly in small-vessel vasculitides


Gene symbol	Gene name	Log2FC (P/M)	FDR

Igj	Immunoglobulin joining chain	8.6779562	2.29E-11

Ly6c2	Lymphocyte antigen 6 complex, locus C2	12.30121239	2.92E-09

Slfn4	Schlafen 4	15.5668286	1.75E-06

Lcn2	Lipocalin 2	7.312076677	3.37E-05

Slpi	Secretory leukocyte peptidase inhibitor	12.73813718	5.33E-05

Ccdc126	Coiled-coil domain containing 126	−8.341365207	0.000225043

Atp5g3	ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9)	−11.69540624	0.000280756

Fsd1l	Fibronectin type III and SPRY domain containing 1-like	−6.703008314	0.000462131

Dnajc12	DnaJ heat shock protein family	−14.11777559	0.000618267

Rbm8a	RNA binding motif protein 8a	−11.28615955	0.001526552

Fat3	FAT atypical cadherin 3	−14.08641235	0.003575335

Col3a1	Collagen, type III, alpha 1	14.61654737	0.003584831

Akap17b	A kinase (PRKA) anchor protein 17B	−10.53057236	0.009607167

Cysltr1	Cysteinyl leukotriene receptor 1	−14.65367542	0.009752316

Sgip1	SH3-domain GRB2-like (endophilin) interacting protein 1	−6.380242524	0.011651515

Pou2af1	POU domain, class 2, associating factor 1	9.055182034	0.019402858

Dnm1	Dynamin 1	−12.9307709	0.050431759

Gene symbol

Igj

Ly6c2

Slfn4

Lcn2

Slpi

Ccdc126

Atp5g3

Fsd1l

Dnajc12

Rbm8a

Fat3

Col3a1

Akap17b

Cysltr1

Sgip1

Pou2af1

Dnm1

Gene name	Log2FC (P/M)	FDR

Immunoglobulin joining chain	8.6779562	2.29E-11

Lymphocyte antigen 6 complex, locus C2	12.30121239	2.92E-09

Schlafen 4	15.5668286	1.75E-06

Lipocalin 2	7.312076677	3.37E-05

Secretory leukocyte peptidase inhibitor	12.73813718	5.33E-05

Coiled-coil domain containing 126	−8.341365207	0.000225043

ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 (subunit 9)	−11.69540624	0.000280756

Fibronectin type III and SPRY domain containing 1-like	−6.703008314	0.000462131

DnaJ heat shock protein family	−14.11777559	0.000618267

RNA binding motif protein 8a	−11.28615955	0.001526552

FAT atypical cadherin 3	−14.08641235	0.003575335

Collagen, type III, alpha 1	14.61654737	0.003584831

A kinase (PRKA) anchor protein 17B	−10.53057236	0.009607167

Cysteinyl leukotriene receptor 1	−14.65367542	0.009752316

SH3-domain GRB2-like (endophilin) interacting protein 1	−6.380242524	0.011651515

POU domain, class 2, associating factor 1	9.055182034	0.019402858

Dynamin 1	−12.9307709	0.050431759


Variable	Baseline	6 months

Energy (Kcal)	2225 ± 1109	1589 ± 384 **

Carbohydrate (g)	273 ± 194	199 ± 74 *

Protein (g)	98 ± 36	78 ± 23 *

Fat (g)	84 ± 39	55 ± 18 **

Starch (g)	148 ± 48	114 ± 36 *

Sugar (g)	121 ± 171	74 ± 64

Non-starch polysaccharide (g)	18 ± 5	14 ± 3 **

Saturated fatty acids (g)	30 ± 16	20 ± 6 **

Monounsaturated fatty acids (g)	29 ± 12	19 ± 7 **

Polyunsaturated fatty acids (g)	16 ± 8	10 ± 4 **

Variable	Baseline	6 months

Energy (Kcal)	2225 ± 1109	1589 ± 384 **

Carbohydrate (g)	273 ± 194	199 ± 74 *

Protein (g)	98 ± 36	78 ± 23 *

Fat (g)	84 ± 39	55 ± 18 **

Starch (g)	148 ± 48	114 ± 36 *

Sugar (g)	121 ± 171	74 ± 64

Non-starch pol	18 ±	14 ± 3 **

ysaccharide (g)	 5

Saturated fatty acids (g)	30 ± 16	20 ± 6 **

Monounsaturated fatty acids (g)	29 ± 12	19 ± 7 **

Polyunsaturated fatty acids (g)	16 ± 8	10 ± 4 **


	Knee painn = 404	Symptomaticknee OAn = 109	OR (95% CI)

Pain unbearable at times	36%	59%	2.0 (1.3 to 3.3)


FEL Clade ScSolanum codons	21, 22, 23, 2930, 32, 34, 35, 38	60	Clade A as forground-	77	103, 106, 109

FEL Clade ScSolanum codons	23, 31	47, 48, 50	Clade C as forground-	80	124


Species	Volume (μL)	Mycotoxin	Extraction Procedure	Detection Technique	LOD (μg/L)	LOQ (μg/L)	Reference

Single mycotoxin

Human	50	OTA	LLE: CH2Cl2	ELISA vs. CE-LIF (CE/laser-induced FD)	0.5	-	[39]

Human	-	OTA	IAC	HPLC-FD	-	-	[42]

Human	-	OTA	SPE: Sep-Pak RP-18. IAC: Ochraprep	HPLC-FD	0.1	0.4	[44]

Human	-	OTA	LLE: CHCl3/HCl	HPLC-FD	0.05	-	[35]

Human	2000	OTA	LLE: CHCl3	HPLC-FD LC-ESI-MS/MS	0.01	0.07	[36]

Human	6000	OTA	SPE: C18	HPLC-FD	0.1	0.2	[41]

Human	1000	OTA	LLE: CHCl3, SPE	HPLC-FD	0.05	-	[37]

Human	2000–3000	OTA	LLE: CHCl3, IAC: Ochraprep	ELISA and HPLC-FD	-	0.050	[38]

Human	-	OTA	IAC: Ochraprep	HPLC-FD	-	0.1	[43]

Human	-	AFB1	IAC: Easi-Extract Aflatoxin	ELISA	-	-	[50]

Rat	100	ZON	LLE: TBME	LC-MS/MS	-	0.5	[48]

Rat	100	ZON	LLE: TBME	HPLC-FD	-	10	[49]

Swine	800	OTA	LLE: CH2Cl2	HPLC	0.1	-	[40]

Chicken	250	DON	LLE: ACN	LC-MS/MS	0.1–0.2	1	[46,47]

Horse	2000	OTA	LLE: CH2Cl2, IAC: Ochratest	ELISA, HPLC-FD	0.015	-	[21]

Multi-mycotoxin

Human	500	OTA, OTα	LLE: CHCl3/isopropanol	HPLC-FD	0.05	0.1	[58]

Chicken	20–250	EN B, EN B1	LLE: ACN	LC/MS/MS, UHPLC-HRMS	0.000091–0.00017	0.025	[45]

Pig	250	EN A, A1, B, B1	LLE: ACN	LC-MS/MS	0.01–0.001	0.1–0.2	[52,53]

Pig	250	DON, T-2, HT-2, OTA, FB1, AFB1, ZON, ZAN, α-ZOL, β-ZOL, α-ZAL, β-ZAL, DOM-1	LLE: ACN	LC-MS/MS	0.01–0.52	0.5–10	[51,54]

Chicken, pig, laying hens, turkey poults	250	ZON, α-ZOL, β-ZOL, ZAN, α-ZAL, β-ZAL	LLE: ACN	LC–MS/MS (U)HPLC–HR-MS	0.004–0.07	0.2–5	[55,57]

Chicken, Pig	250	DON, 3-ADON, 15-ADON, DOM-1	LLE: ACN	LC–MS/MS	0.01–0.7	0.1–2	[56]

Fish	250	AFB1, AFB2, AFG1, AFG2, OTA, FUS-X, STG, FB1, FB2, FB3, BEA, EN A, EN A1, EN B, EN B1	DLLME: ACN/EtOAc	LC/MS/MS	0.1–12.0	1.5–17.0	[59]

Species	Volume (μL)	Mycotoxin	Extraction Procedure

Single mycotoxin

Human	50	OTA	LLE: CH2Cl2

Human	-	OTA	IAC

Human	-	OTA	SPE: Sep-Pak RP-18. IAC: Ochraprep

Human	-	OTA	LLE: CHCl3/HCl

Human	2000	OTA	LLE: CHCl3

Human	6000	OTA	SPE: C18

Human	1000	OTA	LLE: CHCl3, SPE

Human	2000–3000	OTA	LLE: CHCl3, IAC: Ochraprep

Human	-	OTA	IAC: Ochraprep

Human	-	AFB1	IAC: Easi-Extract Aflatoxin

Rat	100	ZON	LLE: TBME

Rat	100	ZON	LLE: TBME

Swine	800	OTA	LLE: CH2Cl2

Chicken	250	DON	LLE: ACN

Horse	2000	OTA	LLE: CH2Cl2, IAC: Ochratest

Multi-mycotoxin

Human	500	OTA, OTα	LLE: CHCl3/isopropanol

Chicken	20–250	EN B, EN B1	LLE: ACN

Pig	250	EN A, A1, B, B1	LLE: ACN

Pig	250	DON, T-2, HT-2, OTA, FB1, AFB1, ZON, ZAN, α-ZOL, β-ZOL, α-ZAL, β-ZAL, DOM-1	LLE: ACN

Chicken, pig, laying hens, turkey poults	250	ZON, α-ZOL, β-ZOL, ZAN, α-ZAL, β-ZAL	LLE: ACN

Chicken, Pig	250	DON, 3-ADON, 15-ADON, DOM-1	LLE: ACN

Fish	250	AFB1, AFB2, AFG1, AFG2, OTA, FUS-X, STG, FB1, FB2, FB3, BEA, EN A, EN A1, EN B, EN B1	DLLME: ACN/EtOAc


Product/active ingredient(s)	Formulation	Country of origin*	2005 availability (n = 29)	Named in the top 3 sellers in 2005 (n = 28)	Mean selling price 2005†

1. artemether/lumefantrine	20/120 mg tablets, co-formulated	Switzerland	21 (72.4%)	5 (17.9%)	$ 7.59

2. artesunate and mefloquine	200 mg and 250 mg tablets, co-packaged	Switzerland	17 (58.6%)	0	$ 7.05

3. artesunate	50 mg tablets	China	6 (20.7%)	0	$ 4.62

4. artesunate	50 mg tablets	France	24 (82.8%)	7 (25.0%)	$ 5.48

5. artesunate	50 mg tablets	Switzerland	8 (27.6%)	0	$ 5.26

6. artesunate	50 mg tablets	Belgium	28 (96.6%)	3 (10.7%)	$ 3.53

7. artesunate	50 mg tablets	India	17 (58.6%)	0	$ 2.51

8. artesunate	100 mg tablets	Belgium	28 (96.6%)	28 (100%)	$ 4.99

9. artesunate	100 mg tablets	Tanzania	7 (24.1%)	1 (3.6%)	$ 2.19

10. artesunate	100 mg tablets	Tanzania	20 (69.0%)	6 (21.4%)	$ 1.92

11. artesunate	100 mg tablets	Kenya	2 (6.9%)	0	$ 2.31

12. artesunate	200 mg tablets	Switzerland	19 (65.5%)	1 (3.6%)	$ 6.72

13. artemether	40 mg tablets	India	8 (27.6% 0	0	$ 2.24

14. artemether	50 mg tablets	China	24 (82.8%)	15 (53.6%)	$ 4.74

15. artemether	180 mg/60 ml suspension	Belgium	18 (62.1%)	0	$ 4.65

16. artemether	300 mg/100 ml suspension	Belgium	3 (10.3%)	0	$ 5.75

17. dihydroartemisinin	60 mg tablets	Korea	18 (62.1%)	0	$ 4.36

18. dihydroartemisinin	60 mg tablets	China	25 (86.2%)	9 (35.7%)	$ 4.55

19. dihydroartemisinin	160 mg/80 ml suspension	China	20 (69.0%)	0	$ 4.18


	Overall survival	Distant disease-free survival

Luminal B	0.87	0.48 to 1.59		0.82	0.49 to 1.38

Adjuvant chemotherapy	0.96	0.38 to 2.45	0.94


Reference strains	International code1	Source

L.(L.)mexicana 	MHOM/BZ/62/BEL21	1

L.(L.)mexicana 	MHOM/BZ/62/M379	1

L.(L.)amazonensis 	IFLA/BR/67/PH8	1

L.(L.)amazonensis 	MHOM/BR/73/M2269	1

L.(L.)garnhami 	MHOM/VE/75/HM76	1

L.(L.)garnhami 	MHOM/VE/76/JAP78	1

L.(L.)pifanoi 	MHOM/VE/57/LL1	1

Reference strains

L.(L.)mexicana

L.(L.)mexicana

L.(L.)amazonensis

L.(L.)amazonensis

L.(L.)garnhami

L.(L.)garnhami

L.(L.)pifanoi

International code1	Source

MHOM/BZ/62/BEL21	1

MHOM/BZ/62/M379	1

IFLA/BR/67/PH8	1

MHOM/BR/73/M2269	1

MHOM/VE/75/HM76	1

MHOM/VE/76/JAP78	1

MHOM/VE/57/LL1	1


IHC	FISH

 	Positive	Negative

Positive	9	5

Negative	2	6

P value	0.183


Amplicon	Test of equality*	Test of variance**

Cav	p = 0.24	p < 0.001


Scenarios (Detailed description in Method section)and total number of respondents	Expected responses (Detailed description in Method section)	Most often selected strategy by French respondents(N = 99)	Agreement in French study with expected choice(Yes/No/Partial)	Most often selected strategy by Swedish respondents[[2]] (N = 59)	Agreement in previous Swedish study with expected choice(Yes/No/Partial)	Agreement between French and previous Swedish study(Yes/No/Partial)

1 N = 96	Quick fix	Quick fix (41%)	Yes	Quick fix (54%)	Yes	Yes

2 N = 97	Quick fix or Symptom- guided MC	Clinical findings-guided MC (53%) (moderate consensus)	No	Symptom-guided MC (44%)	Yes	No

3 N = 91	Try again	2nd opinion (21%) or try again (20%)	Partial	Try again (42%)	Yes	Partial

4 N = 95	Symptom-guided MC or (possibly) Clinical findings-guidedMC	Symptom-guided MC (39%) or Clinical findings- guided MC(39%)	Yes	Symptom-guided MC (46%)	Yes	Yes

5 N = 95	Try again or External help-keep in touch	2nd opinion (27%)	No	Try again (25%) or Clinical findings- guided MC(24%)	Yes	No

6 N = 92	Try again or External help-keep in touch	External help- keep in touch (27%) or try again (26%)	Yes	Try again (37%)	Yes	Yes

7 N = 92	Try again or external help-keep in touch	2nd opinion (48%)	No	Try again (32%)	Yes	No

8 N = 92	2ndopinion	2nd opinion (71%) (excellent consensus)	Yes	2ndopinion (59%)	Yes	Yes

9 N = 91	2ndopinion	2nd opinion (61%) (moderate consensus)	Yes	2ndopinion (59%)	Yes	Yes


	Personality Disorder

	Passednumber, rate

Hand lowering	55, 71.4%

Moving hands apart	52, 67.5%

Mosquito hallucination	44, 57.1%

Taste hallucination	55, 71.4%

Arm rigidity	52, 67.5%

Dream	38, 49.4%*

Age regression	65, 84.4%

Arm immobilization	42, 54.5%

Anosmia to ammonia	16, 20.8%

Hallucinated voice	7, 9.1%

Negative visual hallucination	23, 29.9%

Posthypnotic amnesia	22, 28.6%*


Gene name	Description	Adjusted P value (DB/WT)	Adjusted P value (GGQL/DB)

Pgam1	Phosphoglycerate mutase 1	<0.0001	0.0038

Igf1	Insulin-like growth factor 1	0.0060	0.0029

Cpeb4	Cytoplasmic polyadenylation element binding protein 4	0.0141	0.0283

Slc38a2	Solute carrier family 38, member 2	0.0000	<0.0001

Vegfa	Vascular endothelial growth factor A	0.0001	0.0005

Banp	BTG3-associated nuclear protein	<0.0001	0.0100

Rbm38	RNA-binding motif protein 38	0.0078	0.0380

Rasgef1b	RasGEF domain family, member 1B	0.0003	0.0037

Anxa3	Annexin A3	<0.0001	0.0309

Cyp1a1	Cytochrome P450, family 1, subfamily a, polypeptide 1	<0.0001	0.0016

Trib1	Tribbles homolog 1 (Drosophila)	0.0004	0.0118

Nphp3	Nephronophthisis 3 (adolescent)	<0.0001	0.0275

Fhl3	Four and a half LIM domains 3	0.0036	0.0045

Serpine1	Serine (or cysteine) peptidase inhibitor, clade E, member 1	<0.0001	0.0016

Acer2	Alkaline ceramidase 2	<0.0001	0.0016

Arhgap32	Rho GTPase activating protein 32	<0.0001	<0.0001

Atf4	Activating transcription factor 4	0.0044	0.0016

Zc3h6	Zinc finger CCCH type containing 6	<0.0001	0.0136

Tet1	Tet methylcytosine dioxygenase 1	0.0006	0.0016

Klk1b26	Kallikrein 1-related petidase b26	0.0146	0.0189

Ppp1r3c	Protein phosphatase 1, regulatory (inhibitor) subunit 3C	0.0000	0.0029

Ttc30b	Tetratricopeptide repeat domain 30B	<0.0001	0.0054

Fign	Fidgetin	<0.0001	0.0195

AI593442	Expressed sequence AI593442	<0.0001	0.0350

5730480H06Rik	RIKEN cDNA 5730480H06 gene	0.0019	0.0029

Gm26703	Predicted gene, 26703	<0.0001	<0.0001


Risk Factor Increase	Risk Factor	Mean % Change in Daily Visits per Risk Factor Increase	T-test p-value

0.01 ppm	Ozone	3.2 (1.4, 5)	0.000

1 μg m-3	PM2.5	-0.2 (-0.6, 0.2)	0.331

1000 spores m-3	Mold Count	-0.2 (-1.1, 0.7)	0.707

10 grains m-3	Weed Pollen	-2.9 (-6.8, 1.1)	0.148

100 grains m-3	Tree Pollen	1.8 (0.9, 2.6)	0.000

10 grains m-3	Grass Pollen	1.6 (-2, 5.4)	0.378

1°F	Temperature	0.2 (0.1, 0.4)	0.007

Risk Factor Increase	Risk Factor	Mean % Change in Daily Visits per Risk Factor Increase	T-test p-value

	O	3.2 (1.

Risk Factor Increase	Risk Factor	Mean % Change in Daily Visits per Risk Factor Increase	T-test p-value

0.01 ppm	zone	4, 5)	0.000

1 μg m-3	PM2.5	-0.2 (-0.6, 0.2)	0.331

1000 spores m-3	Mold Count	-0.2 (-1.1, 0.7)	0.707

10 grains m-3	Weed Pollen	-2.9 (-6.8, 1.1)	0.148

100 grains m-3	Tree Pollen	1.8 (0.9, 2.6)	0.000

10 grains m-3	Grass Pollen	1.6 (-2, 5.4)	0.378

1°F	Temperature	0.2 (0.1, 0.4)	0.007


Knockout mouse	Phenotype	Reference

TRPC1	No effect on Ang II-induced cardiac hypertrophy	(39)

Reduced pathological cardiac hypertrophy by double knockout with TRPC4

TRPC3	Resistant to pressure-overload-induced cardiac remodeling	(4, 5, 18)

Reduced ischemia–reperfusion (I/R) injury by triple knockout with TRPC6 and TRPC7	(59)

TRPC4	No effect on Ang II-induced cardiac hypertrophy	(39)

Reduced pathological cardiac hypertrophy by double knockout with TRPC4

TRPC5	No further reduction of pathological cardiac hypertrophy to that of double knockout of TRPC1/C4	(39)

TRPC6	Resistant to pressure-overload induced cardiac remodeling	(18)

Reduced I/R injury by triple knockout with TRPC3 and TRPC7	(59)

TRPC7	Reduced I/R injury by triple knockout with TRPC3 and TRPC6	(59)

Knockout mouse	Phenotype	Reference

TRPC7	Reduced I/R injury by triple knockout with TRPC3 and TRPC6	(59)


Category	Variables	Key references

Personal social learning indicators	Willingness to share ideas with other stakeholders	Pelling and High (2005); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray, Roux, and Hill (2010); Muro and Jeffrey (2012); Bos, Brown, and Farrelly (2013); Cundill et al. (2013).

	Development of trust among stakeholders	Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Cundill et al. (2013)

	Participation by all stakeholders	Pelling et al. (2008); Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012)

	Capacity for conflict resolution	Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)

	Collective action towards project goals	Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013)

	Continuous interaction and feedback	Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010)

	Flexibility in planning and implementation	Pelling and High (2005); Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)

	Willingness to share information	Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013)

Organisational variables	Empowerment of junior employees to experiment	Pelling and High (2005); Pelling et al. (2008); Nilsson and Swartling (2009); Cundill (2010); Bos et al. (2013)

	Existence of processes to translate feedback into changed practices	Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Bos et al. (2013); Tàbara et al. (2010)

	Sufficient budget to regularly engage with stakeholders	Cundill (2010); Roux et al. (2011); Murray et al. (2010); Cundill et al. (2013)

	Continuous updating of project or planning processes	Nilsson and Swartling (2009); Muro and Jeffrey (2012); Tàbara et al. (2010).

	Support for locally initiated projects	Bos et al. (2013); Cundill et al. (2013)

	Development of local stakeholders’ capacity to engage with projects or interventions	Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)

Category

Personal social learning indicators

Organisational variables

Variables	Key references

Willingness to share ideas with other stakeholders	Pelling and High (2005); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray, Roux, and Hill (2010); Muro and Jeffrey (2012); Bos, Brown, and Farrelly (2013); Cundill et al. (2013).

Development of trust among stakeholders	Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Cundill et al. (2013)

Participation by all stakeholders	Pelling et al. (2008); Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012)

Capacity for conflict resolution	Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)

Collective action towards project goals	Pelling and High (2005); Pelling et al. (2008); Collins and Ison (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013)

Continuous interaction and feedback	Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Murray et al. (2010)

Flexibility in planning and implementation	Pelling and High (2005); Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)

Willingness to share information	Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012); Bos et al. (2013)

Empowerment of junior employees to experiment	Pelling and High (2005); Pelling et al. (2008); Nilsson and Swartling (2009); Cundill (2010); Bos et al. (2013)

Existence of processes to translate feedback into changed practices	Pelling et al. (2008); Cundill (2010); Roux et al. (2011); Murray et al. (2010); Muro and Jeffrey (2012); Bos et al. (2013); Tàbara et al. (2010)

Sufficient budget to regularly engage with stakeholders	Cundill (2010); Roux et al. (2011); Murray et al. (2010); Cundill et al. (2013)

Continuous updating of project or planning processes	Nilsson and Swartling (2009); Muro and Jeffrey (2012); Tàbara et al. (2010).

Support for locally initiated projects	Bos et al. (2013); Cundill et al. (2013)

Development of local stakeholders’ capacity to engage with projects or interventions	Cundill and Fabricius (2009); Collins and Ison (2009); Nilsson and Swartling (2009); Cundill (2010); Roux et al. (2011); Muro and Jeffrey (2012)


Tissue	miRNA	Molecular targets	Functions	Reference

Aging heart	miR-21 ↑	ERK–MAP kinase signaling	Profibrotic [role on cardiac fibroblast (CFs)]	(51)

Aging heart	miR-22 ↑	Mimecan/Osteoglycin	Accelerate CF senescence and migration	(52)

Aging heart	miR-18 and miR-19 ↓	Thrombospondin-1 and connective tissue growth factor	Anti-heart failure-related fibrosis during aging	(58)

Aging heart	miR-17-3p ↓	PAR-4	Reduce CF cellular senescence	(61)

Aging heart	miR-34a ↑	Phosphatase 1 nuclear targeting subunit	Increase age-related cardiomyocyte apoptosis and cardiac dysfunction	(62)

Vascular aging	miR-34a ↑	SIRT1	Stimulates senescence in endothelial cell and vascular smooth muscle cells	(68, 71)

Vascular aging	miR-217 ↑	SIRT1	Stimulates endothelial senescence decreasing nitric oxide	(73)

Vascular aging	miR-29 ↑	Collagen and elastin	Extracellular matrix impairment (risk of age-related aortic aneurism)	(74–77)

Vascular aging	miR-146 ↑ or ↓	IRAK and NOX4	Pro-inflammation or anti-oxidative stress	(78, 79)

Vascular aging	miR-92 ↓	Tumor necrosis factor α receptor 1 and collagen type 1	miR-92 reduction mimic arterial aging	(80)

Tissue	miRNA

Aging heart	miR-21 ↑

Aging heart	miR-22 ↑

Aging heart	miR-18 and miR-19 ↓

Aging heart	miR-17-3p ↓

Aging heart	miR-34a ↑

Vascular aging	miR-34a ↑

Vascular aging	miR-217 ↑

Vascular aging	miR-29 ↑

Vascular aging	miR-146 ↑ or ↓

Vascular aging	miR-92 ↓

Molecular targets	Functions	Reference

ERK–MAP kinase signaling	Profibrotic [role on cardiac fibroblast (CFs)]	(51)

Mimecan/Osteoglycin	Accelerate CF senescence and migration	(52)

Thrombospondin-1 and connective tissue growth factor	Anti-heart failure-related fibrosis during aging	(58)

PAR-4	Reduce CF cellular senescence	(61)

Phosphatase 1 nuclear targeting subunit	Increase age-related cardiomyocyte apoptosis and cardiac dysfunction	(62)

SIRT1	Stimulates senescence in endothelial cell and vascular smooth muscle cells	(68, 71)

SIRT1	Stimulates endothelial senescence decreasing nitric oxide	(73)

Collagen and elastin	Extracellular matrix impairment (risk of age-related aortic aneurism)	(74–77)

IRAK and NOX4	Pro-inflammation or anti-oxidative stress	(78, 79)

Tumor necrosis factor α receptor 1 and collagen type 1	miR-92 reduction mimic arterial aging	(80)


	Cisplatin excretion

	0–12 h

	SCT (R/p value)	ULiR (p value)

Number variation (range)

Haemoglobin	0.000/1.000	0.7375

Leukocytes	0.101/0.471	0.4833

Neutrophils	0.125/0.372	0.4689

Lymphocytes	0.071/0.613	0.2391

Platelets	−0.170/0.223	0.3899

Creatinine	−0.055/0.698	0.7700

Creatinine clearance	0.009/0.951	0.9380

	SCT (R/p value)	ULoR (p value)

Severity by grade

Anaemia	0.073/0.601	0.3811

Leukopenia	0.041/0.771	0.8971

Neutropenia	−0.007/0.960	0.9863

Lymphopenia	0.071/0.613	0.4500

Thrombocytopenia	0.038/0.786	0.3511

Increase in serum creatinine	−0.069/0.627	0.6263

Reduction in creatinine clearance	−0.100/0.483	0.4715

Nausea	−0.065/0.642	0.6791

Vomiting	−0.101/0.471	0.4140

Diarrhoea	−0.195/0.161	0.1685


Type of TEAE observed	No. (%) of subjects

ESRD subjects (n = 8)	Healthy subjects (n = 8)	Total (N = 16)

Dosing after hemodialysis	Dosing before hemodialysis

Any TEAE	3 (37.5)	2 (25.0)	1 (12.5)	5 (31.3)

Upper RTI	2 (25.0)	0	0	2 (12.5)

Viral upper RTI	1 (12.5)	0	0	1 (6.3)

Dizziness	1 (12.5)	0	0	1 (6.3)

Headache	0	1 (12.5)	0	1 (6.3)

Infusion site erythema	0	0	1 (12.5)	1 (6.3)

Bronchospasm	0	1 (12.5)	0	1 (6.3)

Papular rash	1 (12.5)	0	0	1 (6.3)

Type of TEAE observed

Any TEAE

Upper RTI

Viral upper RTI

Dizziness

Headache

Infusion site erythema

Bronchospasm

Papular rash


Species (tax id, short name)	Number of proteins	Number of PPI	Source

E. coli K12 (83333, eco)	4121	216426	SNDB [22]

S. typhimurium (99287, stm)	4239	94609	SNDB [22]

C. crescentus (190650, ccr)	3365	40524	SNDB [22]

Yeast (4932, sce)	4738	15417	DIP [13]

Fly (7227, dme)	7165	23484	DIP [13]

Worm (6239, cel)	3029	3393	DIP [13]

Species (tax id, short name)	Number of proteins	Number of PPI	Source

Worm (6239, cel)	3029	3393	DIP [13]


Age (yr)*	37.14 ± 7.58

Employment record (yr)*	11.48±4.47

Educational level**	Two trained courses after diploma	8(2.23)

Baccalaureate	311(86.11)

Masters/doctorate	42(11.66)

Marital status **	Married	72(19.91)

Single	279(77.21)

Divorced/Widow	10(2.88)

Gender	Female	339(93.94)

Male	22(6.06)

Current work setting **	General hospital	232(64.35)

Primary health care center	109(30.21)

Private hospital	20(5.54)

Marital status **	Single	279(77.21)

Divorced/Widow	10(2.88)

Gender	Female	339(93.94)

Male	22(6.06)

Current work setting **	General hospital	232(64.35)

Primary health care center	109(30.21)

Private hospital	20(5.54)


Meta-Method	Mean Error

Fisher	0.276

POE with Bss/Wss 	0.375

POE with IC 	0.301

GeneMeta	0.525

RankProd	0.475

Simple	0.617

Cross-Validation	0.329

mDEDS	0.277


Question	Level of ecological framework targeted

Introduction

1. How long have you worked/lived in [name of agency or community]?	N/A

Meaning of Good Health

First, I want you to think about your own health and life.	Intra-Personal

2. What do you consider “good health”?

3. What do you think it means to live a healthy lifestyle?

Now I want you think about [insert name of community]. I’d like for you to think about the community residents that you see every day and interact with either personally or for your job. I also want you to think about the community’s physical environment, stores, restaurants, health and human services, community programs, and so on.	Community/Institutional

4. What does it mean for a community to be “healthy”?

5. Do you consider your community to be healthy?

6. How would you rate the health of this community as a whole on a scale of 1 to 5, with 1 being poor and 5 being excellent?

Probe: What factors did you take into account with your rating?

Enabling and Inhibiting Factors of Good Health

7. What are the values around being healthy in this community?	Inter-Personal

8. What are the unique characteristics (strengths) in [insert name of community] that help residents in being healthy?

Probe: What other characteristics within this community support being healthy?

9. What are the unique characteristics (weaknesses) in [insert name of community] that prevent residents from being healthy?

Probe: What other characteristics within your community discourage residents from being healthy?

10. Which of these characteristics, good and not good, are specific to the [insert Native/MSFW/Latino] culture in this community?

11. What are the biggest (or most important/pressing) health-related concerns in this community?	Community/Institutional

Probe: In your point of view, what are the factors that contribute to these health problems?

12. What resources are available or in place in [insert name of community] to support healthy living among the residents?	Macro Level/Public Policy

Probe: How much are these resources used by community residents?

Probe: How widely known are these resources by community residents?

Wrap Up

13. What are other important health issues in this community that we have not discussed so far?	All

Question

Introduction

1. How long have you worked/lived in [name of agency or community]?

Meaning of Good Health

First, I want you to think about your own health and life.

2. What do you consider “good health”?

3. What do you think it means to live a healthy lifestyle?

Now I want you think about [insert name of community]. I’d like for you to think about the community residents that you see every day and interact with either personally or for your job. I also want you to think about the community’s physical environment, stores, restaurants, health and human services, community programs, and so on.

4. What does it mean for a community to be “healthy”?

5. Do you consider your community to be healthy?

6. How would you rate the health of this community as a whole on a scale of 1 to 5, with 1 being poor and 5 being excellent?

Probe: What factors did you take into account with your rating?

Enabling and Inhibiting Factors of Good Health

7. What are the values around being healthy in this community?

8. What are the unique characteristics (strengths) in [insert name of community] that help residents in being healthy?

Probe: What other characteristics within this community support being healthy?

9. What are the unique characteristics (weaknesses) in [insert name of community] that prevent residents from being healthy?

Probe: What other characteristics within your community discourage residents from being healthy?

10. Which of these characteristics, good and not good, are specific to the [insert Native/MSFW/Latino] culture in this community?

11. What are the biggest (or most important/pressing) health-related concerns in this community?

Probe: In your point of view, what are the factors that contribute to these health problems?

12. What resources are available or in place in [insert name of community] to support healthy living among the residents?

Probe: How much are these resources used by community residents?

Probe: How widely known are these resources by community residents?

Wrap Up

13. What are other important health issues in this community that we have not discussed so far?

Level of ecological framework targeted

Introduction

N/A

Meaning of Good Health

Intra-Personal

Community/Institutional

Enabling and Inhibiting Factors of Good Health

Inter-Personal

Community/Institutional

Macro Level/Public Policy

Wrap Up

All


Drug	Cases (n=32)	Controls (n=64)	p

Zidovudine

Yes	11	12	0.15

No	21	52

Lamivudine

Yes	17	28	0.5

No	15	36

Tenofovir

Yes	15	35	0.6

No	17	29

Emtricitabine

Yes	4	20	0.08

No	28	44

Emtricitabine+tenofovir

Yes	4	20	0.08

No	28	44

Zidovudine+lamivudine

Yes	7	11	0.8

No	25	53

Didanosine

Yes	4	4	0.4

No	28	60

Abacavir

Yes	3	4	0.6

No	29	60

Efavirenz

Yes	11	20	0.9

No	21	44

Nevirapine

Yes	3	6	1

No	29	58

Atazanavir

Yes	6	16	0.6

No	26	48

Fosamprenavir

Yes	2	2	0.6

No	30	62

Lopinavir/ritonavir

Yes	2	5	1

No	30	59


Characteristics

Gender

Male

Female

Age (years)

20–39

40–59

≥ 60

Educational level

Low-intermediate education

High education

Monthly income

< 500 Kuwaiti Dinars (KD)

500–1000 Kuwaiti Dinars (KD)

> 1000 Kuwaiti Dinars (KD)

Personal health

Excellent

Very good

Good/Fair

Chronic disease

Yes

No


Exposure to iAs in Water	Na	Range	AM	GM	GSD

iAs, current concentration (ppb)	258	3.1	215.2	42.9	24.4	2.9

iAs, cumulative exposure 1993-2008 (ppm.years)	255	0.0	6.73	1.8	1.3	2.3

iAs, cumulative exposure 1993-1997 (ppm.years)	255	0.0	5.8	0.7	0.5	2.8

iAs, cumulative exposure 1998-2002 (ppm.years)	255	0.0	4.5	0.6	0.5	2.3

iAs, cumulative exposure 2002-2007 (ppm.years)	255	0.0	1.2	0.5	0.4	2.1

Metabolites of iAs in Urine (ng/mL)

tAs	256	2.3	233.7	41.2	24.7	2.8


Variable	Survivors (n = 36)	Nonsurvivors (n = 25)	P value

cTnT (pg/mL), median (IQL) 	20 (18–24)	34.5 (27.5–41.5)	<0.05*


Gene	Positions and nt sequence sizes (bp)	Start and stop codons	tRNA Anti-codons	Intergenic nt (bp)

	PL (5’	PC (5’-3		PC	PL		P	P


Materials employed	Composition	Manufacturer

GC Fuji II Universal Restorative	Powder: 95% fluoroaluminosilicate glass (amorphous)5% polyacrylic acid	G.C. Corporation, Tokyo, Japan

Liquid: 50% distilled water40% polyacrylic acid

GC Fuji II Capsule	Powder/liquid ratio (g/g) 0.30/0.11	G.C. Corporation, Tokyo, Japan

GC Fuji II Universal Restorative Liquid	50% distilled water40% polyacrylic acid	G.C. Corporation, Tokyo, Japan

GC Dentin Conditioner	10% polyacrylic acid	G.C. Corporation, Tokyo, Japan

Materials employed	Composition	Manufacturer

GC Fuji II Univ	Powder: 95% fluoroaluminosilicate glass (amorphous)5% polyacrylic acid	G.C. Corporation,

Liquid: 50% distill

Materials employed	Composition	Manufacturer

ersal Restorative	ed water40% polyacrylic acid	 Tokyo, Japan

GC Fuji II Capsule	Powder/liquid ratio (g/g) 0.30/0.11	G.C. Corporation, Tokyo, Japan

GC Fuji II Universal Restorative Liquid	50% distilled water40% polyacrylic acid	G.C. Corporation, Tokyo, Japan

GC Dentin Conditioner	10% polyacrylic acid	G.C. Corporation, Tokyo, Japan


Data set	Number of instances	Number of attributes

Sonar	208	60

Live disorder	345	6

Breast cancer	680	10

Cystic fibrosis	177	Depends on q

Leukemia	355	Depends on q

Lung cancer	91	54675


 	Group O (n = 40)	Group L (n = 39)	p valuesa

Surgical indication	 	 	0.968b

 Inflammation	3 (7.50)	3 (7.69)

 Stricture	24 (60.00)	23 (58.97)

 Internal fistula/mass	11 (27.50)	10 (25.64)

 Hemorrhage	2 (5.00)	3 (7.69)

Type of surgery 	 	 	0.629b

 Small bowel resection	11 (27.50)	10 (25.64)

 Ileocolic resection	21 (52.50)	24 (61.54)

 Colonic resection	8 (20.00)	5 (12.82)

Hand-assisted anastomosis	 	11 (28.21)

Length of incision (cm)	10.30 ± 1.79	5.00 ± 1.23	<0.001

Operation duration (min)	86.85 ± 24.31	121.53 ± 33.62	<0.001

Blood loss (mL)	122.25 ± 53.61	54.10 ± 21.97	<0.001


	No history of MTSS	History of MTSS	P-value	Effect size (r)

Navicular Drop (mm)	7.1 ± 2.0	7.1 ± 1.9	0.98	0.01

Leg Heel Alignment (°)	5.0 ± 1.4	5.1 ± 2.0	0.72	0.08

	history of MTSS	MTSS	e	ze (r)

Navicular Drop (mm)	7.1 ± 2.0	7.1 ± 1.9	0.98	0.01

Leg Heel Alignment (°)	5.0 ± 1.4	5.1 ± 2.0	0.72	0.08


<underline>Sociodemographics</underline>	<underline>% of full sample</underline>

Age (mean, SD)	32.6, 13.0

Minority/racial group member	50.2

Not married	45.0

No. children in household	49.6

No education beyond high school	37.4

Not employed	45.4

Income below federal poverty line	17.9

<underline>Physical health</underline>

Not pregnant	94.7

Smokes	13.6

Fair/poor health	17.3

<underline>Mental health</underline>

PTSD symptoms	6.3

Anxiety symptoms	21.8

Depression symptoms	13.7

Overwhelmed by stress	12.5

<underline>Mental health help</underline>

Poor mental health	14.2

Perceived need for mental health help	23.2

Utilized mental health help	9.8

<underline>Adult victimization</underline>

Intimate partner violence	9.9

Physically assaulted	19.7

Sexually assaulted	10.6

Death of someone close	29.7

<underline>Childhood victimization</underline>

Lived in foster care	3.4

Lived with someone abusing substances	22.3

Lived with someone mentally ill	16.8

Lived with mother victimized by violence	18.4

Lived with someone incarcerated	7.6

Emotionally abused by adult in home	18. 4

Physically assaulted	19.1

Sexually assaulted	11.2

Sociodemographics	% of full sample

Age (mean, SD)	32.6, 13.0

Minority/racial group member	50.2

Not married	45.0

No. children in household	49.6

No education beyond high school	37.4

Not employed	45.4

Income below federal poverty line	17.9

Physical health

Not pregnant	94.7

Smokes	13.6

Fair/poor health	17.3

Mental health

PTSD symptoms	6.3

Anxiety symptoms	21.8

Sociodemographics	% of full sample

Depression symptoms	13.7

Overwhelmed by stress	12.5

Mental health help

Poor mental health	14.2

Perceived need for mental health help	23.2

Utilized mental health help	9.8

Adult victimization

Intimate partner violence	9.9

Physically assaulted	19.7

Sexually assaulted	10.6

Death of someone close	29.7

Childhood victimization

Lived in foster care	3.4

Lived with someone abusing substances	22.3

Lived with someone mentally ill	16.8

Lived with mother victimized by violence	18.4

Lived with someone incarcerated	7.6

Emotionally abused by adult in home	18. 4

Physically assaulted	19.1

Sexually assaulted	11.2


	GUH (N = 34)	WHC (N = 21)	Total (N = 55)

Age (N = 55)	M = 55.4 SD = 8.2	M = 53.7 SD = 6.7	M = 54.7 SD = 7.6

Race/Ethnicity #

 White (N = 19)	50%	10.5%	35.8%

 African American (N = 30)	38.2%	89.5%	56.6%

 Other (N = 4)	11.8%	0	7.5%

Education

 < HS grad (N = 14)	20.6%	33.3%	25.5%

 Voc/trade or some college (N = 12)	14.7%	33.3%	21.8%

 College Graduate (N = 7)	20.6%	0	12.7%

 Graduate work/degree (N = 22)	44.1%	33.3%	40.0%

Marital Status

 Married (N = 37)	70.6%	61.9%	67.3%

 Other (N = 18)	29.4%	38.1%	32.7%

Internet access at home/work

 Yes (N = 41)	82.4%	61.9%	74.5%

 No (N = 14)	17.6%	38.1%	25.5%

Home/Work Computer Internet Usage (among those with access at home/work)

 Few times yr/few times month (N = 7)	7.1%	38.5%	17.1%

 Once/twice a wk (N = 5)	14.3%	7.7%	12.2%

 Daily (N = 29)	78.6%	53.8%	70.7%

Receiving Health Related Information #

 Prefers Internet (N = 23)	47.1%	36.8%	43.4%

 Prefers Booklet (N = 30)	52.9%	63.2%	56.6%

Willingness to Read Prostate Cancer Info on the Internet #

 Definitely/Probably would (N = 42)	76.5%	84.2%	79.3%

 Definitely/Probably would not (N = 11)	23.5%	15.8%	20.7%

Awareness of Disagreement in Medical Community Regarding Whether to Screen for PrCa

 Unaware of disagreement (N = 45)	82.4%	81.0%	81.8%

 Aware of disagreement (N = 4)	2.9%	14.3%	7.3%

 Not Sure (N = 6)	14.7%	4.8%	10.9%

	GUH (N = 34)	WHC (N = 21)

Age (N = 55)	M = 55.4 SD = 8.2	M = 53.7 SD = 6.7

Race/Ethnicity #

White (N = 19)	50%	10.5%

African American (N = 30)	38.2%	89.5%

Other (N = 4)	11.8%	0

Education

< HS grad (N = 14)	20.6%	33.3%

Voc/trade or some college (N = 12)	14.7%	33.3%

College Graduate (N = 7)	20.6%	0

Graduate work/degree (N = 22)	44.1%	33.3%

Marital Status

Married (N = 37)	70.6%	61.9%

Other (N = 18)	29.4%	38.1%

Internet access at home/work

Yes (N = 41)	82.4%	61.9%

No (N = 14)	17.6%	38.1%

Home/Work Computer Internet Usage (among those with access at home/work)

Few times yr/few times month (N = 7)	7.1%	38.5%

Once/twice a wk (N = 5)	14.3%	7.7%

Daily (N = 29)	78.6%	53.8%

Receiving Health Related Information #

Prefers Internet (N = 23)	47.1%	36.8%

Prefers Booklet (N = 30)	52.9%	63.2%

Willingness to Read Prostate Cancer Info on the Internet #

Definitely/Probably would (N = 42)	76.5%	84.2%

Definitely/Probably would not (N = 11)	23.5%	15.8%

Awareness of Disagreement in Medical Community Regarding Whether to Screen for PrCa

Unaware of disagreement (N = 45)	82.4%	81.0%

Aware of disagreement (N = 4)	2.9%	14.3%

Not Sure (N = 6)	14.7%	4.8%


Drug	n	Median Dosage (mg/kg/day)	Median Length of Treatment (Days)	Side Effects (n)

Rifampicin	415	17.5	240	Itch, vomit and headache (1); rash (1); hypertransaminasemia (4)

Pyrazinamide	411	27	95	Hypertransaminasemia (7); vomit and malaise (1); epigastric pain (1); hyperuricemia (5); drug induced hepatitis (1)

Isoniazid	396	10	242	Drug induced hepatitis (1); hypertransaminasemia (4)

Ethambutol	245	17	86	Vomit and malaise (1); neutropenia (1); drug induced hepatitis (1); epigastric pain (1)

Streptomycin	35	19	31

Moxifloxacin	31	10.3	161	Tendinopathy (1); long QT syndrome (1)

Linezolid	17	19.1	108

Amikacin	12	16.8	24,5

Cycloserine	11	14.1	220

Levofloxacin	7	11.6	202

PAS 1	6	118	172.5

Ethionamide	6	15.4	91.6

Clarithromycin	5	15.6	39.6

Kanamicina	1	10	142

Ciprofloxacin	4	17	238	Vomit and weight loss (1)

Drug	n	Median Dosage (mg/kg/day)	Median Length of Treatment (Days)

Rifampicin	415	17.5	240

Pyrazinamide	411	27	95

Isoniazid	396	10	242

Ethambutol	245	17	86

Streptomycin	35	19	31

Moxifloxacin	31	10.3	161

Linezolid	17	19.1	108

Amikacin	12	16.8	24,5

Cycloserine	11	14.1	220

Levofloxacin	7	11.6	202

PAS 1	6	118	172.5

Ethionamide	6	15.4	91.6

Clarithromycin	5	15.6	39.6

Kanamicina	1	10	142

Ciprofloxacin	4	17	238

Side Effects (n)

Itch, vomit and headache (1); rash (1); hypertransaminasemia (4)

Hypertransaminasemia (7); vomit and malaise (1); epigastric pain (1); hyperuricemia (5); drug induced hepatitis (1)

Drug induced hepatitis (1); hypertransaminasemia (4)

Vomit and malaise (1); neutropenia (1); drug induced hepatitis (1); epigastric pain (1)

Tendinopathy (1); long QT syndrome (1)

Vomit and weight loss (1)


Genes groupa	Number of genesb

Glucose-dependent	667 (18%)

Upregulated genes	349

Downregulated genes	318

CcpA-dependent	407 (11%)

Upregulated by CcpA	197

Downregulated by CcpA	210

Regulated by glucose in a CcpA-dependent manner	361 (10%)

Upregulated genes	170

Downregulated genes	191

Regulated by glucose in a CcpA-independent manner	303 (8%)

Upregulated genes	177

Downregulated genes	126

Regulated by CcpA in absence of glucose	43 (1%)

Upregulated by CcpA	8

Downregulated by CcpA	35

Regulated by CcpA independent of glucose	3 (0.08%)

Upregulated by CcpA	2

Downregulated by CcpA	1

Atypical regulation	112 (0.3%)

Upregulated genes	39

Downregulated genes	73

Genes groupa	Number of genesb

Glucose-dependent	667 (18%)

Upregulated genes	349

Downregulated genes	318

CcpA-dependent	407 (11%)

Upregulated by CcpA	197

Downregulated by CcpA	210

Regulated by glucose i	3

Genes groupa	Number of genesb

n a CcpA-dependent manner	61 (10%)

Upregulated genes	170

Downregulated genes	191

Regulated by glucose in a CcpA-independent manner	303 (8%)

Upregulated genes	177

Downregulated genes	126

Regulated by CcpA in absence of glucose	43 (1%)

Upregulated by CcpA	8

Downregulated by CcpA	35

Regulated by CcpA independent of glucose	3 (0.08%)

Upregulated by CcpA	2

Downregulated by CcpA	1

Atypical regulation	112 (0.3%)

Upregulated genes	39

Downregulated genes	73


No.	Disease	Medicine	Formulation	Strength	Target size pack

1	Intestinal parasite	Albendazole	tablet	200 mg	2

2	Infectious disease	Amoxicillin	capsule	250 mg	10

	Infectious disease	Amoxicillin	suspension	125 mg	100 ml

3		Aminophyllin	injection	25 mg/ml	1 vial

4	Infectious disease	Amoxicillin_Clavulanic acid	tablet	125 mg + 125 mg, tab	10

	Infectious disease	Amoxicillin_Clavulanic acid	suspension	125 mg + 31.25 mg	100 ml

	Infectious disease	Amoxicillin_Clavulanic acid	suspension	250 mg + 62.50 mg	100 ml

5	Infectious disease	Azithromycin	capsule	250 mg	6

	Infectious disease	Azithromycin	suspension	200 mg/5 ml	100 ml

6	Asthma	Beclomethason	inhaler	50 mg/day	1 inhaler (200 doses)

7	Infectious disease	Benzylpenicillin	injection	600 mg = 1 million IU	1 vial

8	Seizure Disorder	Carbamazepine	tablet	100 mg	20

	Seizure Disorder	Carbamazepine	suspension	100 mg/5 ml	100 ml

9	Infectious disease	Cefazolin	injection	1 g, vial	1 vial

10	Infectious disease	Ceftriaxone	injection	500 mg vial	1 vial

11	Infectious disease	Chloramphenicol	tablet	250 mg	10

	Infectious disease	Chloramphenicol	injection	1 g, vial	1 vial

12	Infectious disease	Chlorpheniramine	tablet	4 mg	24

13	Infectious disease	Clarithromycin	suspension	125 mg/ 5 ml	100 ml

	Infectious disease	Clarithromycin	tablet	125 mg	10

14	Infectious disease	Cotrimoxazole	tablet	100 mg + 20 mg (also expressed as 400 mg + 80 mg)	10

	Infectious disease	Cotrimoxazole	suspension		100 ml

15	Seizure Disorder	Diazepam	tablet	5 mg	10

16	Anemia	Ferrous salt	suspension	30 mg/5 ml	100 ml

17	Fungal infection	Fluconazole	capsule	150 mg	6

18	Infectious disease	Gentamycin	injection	10 mg/ml	1 vial

19	Pain/inflammation	Ibuprofen	tablet	2 mg	24

	Pain/inflammation	Ibuprofen	suspension		100 ml

20	Tuberculosis	Isoniazide	tablet	100 mg	56

21	Pain	Morphine	tablet	10 mg	56

	Pain	Morphine	oral solution	10 mg/5 ml	100 ml

22	Dehydration	ORS	sachet	500 ml	1 sachet

23	Pain/inflammation	Paracetamol	tablet	250 mg	10

	Pain/inflammation	Paracetamol	suppository	125 mg	10

	Pain/inflammation	Paracetamol	suppository	250 mg	10

	Pain/inflammation	Paracetamol	suspension	125 mg	100 ml

24	Seizure Disorder	Phenobarbital	tablet	30 mg	10

	Seizure Disorder	Phenobarbital	injection	100 mg/ml	1 vial

25	Seizure Disorder	Phenytoin	tablet	50 mg,	90

	Seizure Disorder	Phenytoin	suspension	25 mg, 30 mg/5 ml	500 ml

26	Infectious disease	Procain penicillin	injection	1 g, vial	1 vial

27	Asthma	Salbutamol	inhaler	100mcg	1 inhaler (200 doses)

28	Xerophthalmia	Vitamin A	capsule	100.000 IU	50

29	Anemia	Vitamin B6	injection	50 mg/ml	1 vial

30	Dehydration	Zinc	tablet	20 mg	14

31	Spacer	Device


Gene Name	Forward primer sequence (5′-3′)	Reverse primer sequence (5′-3′)

β-actin	ACTGGGACGACATGGAGAAGATC	AAACCTTACCACTCCCGCC

ADRA1B	TCTGGTCGCTGTGCGTGAT	ATCAAGACCACCAAGACATCCG

ARL3	CATCCCTTGCTCTACATTACTTCC	AAACGACGGGTGCCACAG

BAP1	ACCCGCACTCCTCCCTTAT	GAGAACCAAGTGGAGCAGACA

TRPA1	AGTAGCGGCAACATGTCCACC	CCAAACTAACCCTGAAAGACCG


PPAR	Human	Mouse	Zebrafish

PPARA

 Genes	1	1	2

 Splice variants	1	1	1 per gene

 Isoforms	1	1	1 per gene

 Size (cds, bp)	1,407	1,407	pparaa: 1,413pparab: 1,380

 Protein similarity to zebrafish	67% for pparaa 74% for pparab	65% for pparaa 71% for pparab

PPARD

 Genes	1	1	2

 Splice variants	1	1	1 per gene

 Isoforms	1	1	1 per gene

 Size (cds, bp)	1,326	1,323	pparda: 1,491ppardb: 1,554

 Protein similarity to zebrafish	71% for pparda 73% for ppardb	70% for pparda 73% for ppardb

PPARG

 Genes	1	1	1

 Splice variants	4	1	1

 Isoforms	2	2	1

 Size (cds, bp)	PPARG1 = 1,434PPARG2 = 1,518	PPARG1 = 1,428PPARG2 = 1,518	pparg: 1,584

 Protein similarity to zebrafish	67%	67%


	Pre-intervention	Post-intervention

	Intervention(n = 43)	Control(n = 30)	Intervention(n = 37)	Control(n = 28)	P-value

Attitudes (agreement with statement)

Teachers do not need to act as role models for being active	5.0	11.5	0.0	7.5	0.09

It is not the role of the teacher to teach movement skills	14.3	10.0	5.7	19.2	0.10

It is not important that children participate in structured active play	9.8	13.3	0.0	0.0	-

Safety concerns limit active play opportunities in the preschool setting	60.0	70.0	38.9	58.3	0.14

It is not the role of the teacher to teach about healthy eating	14.5	3.5	2.8	15.5	0.07

Parents should be able to send any type of food to school with their child.	7.3	3.3	0.0	3.7	0.25

It is alright to sell chocolates and sweets for fundraising	56.1	56.5	59.0	48.0	0.39

Confidence

I am confident that I can teach movement skills to children.	97.6	90.0	97.3	95.7	0.73

I am confident in talking to parents about their child's movement skills.	80.5	96.7	97.0	90.9	0.33

I am confident in talking to parents about their child's lunchbox contents	76.9	89.7	89.7	95.8	0.40

Confident talking to parents about their child's television viewing	47.5	78.6	68.8	75.0	0.68

Knowledge of recommended guidelines

Daily serves of fruit	100.0	93.0	94.5	96.0	0.79

Daily serves of vegetables	89.7	96.6	94.3	87.5	0.36

Recreational screen time (TV/DVDs) (hrs/day)	84.2	62.1	73.5	87.0	0.22

	Pre-intervention	Post-intervention

	Intervention(n = 43)	Control(n = 30)	Intervention(n = 37)	Control(n = 28)	P-value

Attitudes (agreement with statement)

Teachers do not need to act	5	11	0	7.	0

 as role models for being active	.0	.5	.0	5	.09

It is not the role of the teacher to teach movement skills	14.3	10.0	5.7	19.2	0.10

It is not important that children participate in structured active play	9.8	13.3	0.0	0.0	-

Safety concerns limit active play opportunities in the preschool setting	60.0	70.0	38.9	58.3	0.14

It is not the role of the teacher to teach about healthy eating	14.5	3.5	2.8	15.5	0.07

Parents should be able to send any type of food to school with their child.	7.3	3.3	0.0	3.7	0.25

It is alright to sell chocolates and sweets for fundraising	56.1	56.5	59.0	48.0	0.39

Confidence

I am confident that I can teach movement skills to children.	97.6	90.0	97.3	95.7	0.73

I am confident in talking to parents about their child's movement skills.	80.5	96.7	97.0	90.9	0.33

I am confident in talking to parents about their child's lunchbox contents	76.9	89.7	89.7	95.8	0.40

Confident talking to parents about their child's television viewing	47.5	78.6	68.8	75.0	0.68

Knowledge of recommended guidelines

Daily serves of fruit	100.0	93.0	94.5	96.0	0.79

Daily serves of vegetables	89.7	96.6	94.3	87.5	0.36

Recreational screen time (TV/DVDs) (hrs/day)	84.2	62.1	73.5	87.0	0.22


Probe Set	z-score	DMFS	Gene Symbol	Gene Title

209648_x_at	4.01	-	SOCS5	suppressor of cytokine signaling 5

208127_s_at	3.75	-	SOCS5	suppressor of cytokine signaling 5

209550_at	3.18	-	NDN	necdin homolog (mouse)

201162_at	3.14	-	IGFBP7	insulin-like growth factor binding protein 7

213910_at	2.87	-	IGFBP7	insulin-like growth factor binding protein 7

212279_at	2.91	+	MAC30	hypothetical protein MAC30

213337_s_at	2.88	+	SOCS1	suppressor of cytokine signaling 1


 	Blood culture/IFAT	Total

Positive	Negative

PCR	Positive	25/29	11/7	36/36

Negative	4/3	10/11	14/14

 	Total	29/32	21/18	50/50


	Control group	Study group	Total analysed

Toes	156 (50 %)	156 (50 %)	312

 Males	37	26	63

 Females	44	58	102

Average age	27.19	25.35	26.27

 Standard deviation	9.48	9.04	9.26

 Median (range)	23 (12–50)	23 (10–50)	23 (10–50)


Variable	Description and unit	Mean	Std. Dev.

Hypertension	1if has hypertension; 0 otherwise	0.43	0.49

Obesity	1 if obese; 0 otherwise	0.31	0.46

Age	In years	55.46	16.06

Marital status	1 if married; 0 otherwise	0.56	0.49

Education	1 if some college or higher; 0 otherwise	0.51	0.49

Employment	1 if employed; 0 otherwise	0.40	0. 49

Income	Annual income in dollars	$40,774	$24,815

Gender	1 if male; 0 if female	0.38	0.48

Race	1 if white; 0 if race other than white	0.90	0.29

Sleep	Number of sleepless days in previous month	8.50	10.56

Drinks	1 if drinks alcohol; 0 otherwise	0.34	0.47

Smokes	1 if smokes; 0 otherwise	0.21	0.41

Exercise	Number of minutes engaged in exercise for the previous week	403.57	674.95

Variable	Description and unit	Mean	Std. Dev.

Income	Annual income in dollars	$40,774	$24,815

Gender	1 if male; 0 if female	0.38	0.48

Race	1 if white; 0 if race other than white	0.90	0.29

Sleep	Number of sleepless days in previous month	8.50	10.56

Drinks	1 if drinks alcohol; 0 otherwise	0.34	0.47

Smokes	1 if smokes; 0 otherwise	0.21	0.41

Exercise	Number of minutes engaged in exercise for the previous week	403.57	674.95


References	Primary outcomes	Secondary outcomes

Fiske (strong)1[17]	There was no difference in sales of healthier food options between intervention and control groups.

Kocken (strong) [20]	Higher sales of healthier food options were observed in intervention groups compared to control groups.


Section of economizer	Condition design

	Length was 250 mm

Evaporator section	Hot water flow was 80°C

	Volumetric flow rate was 5 l/min

Adiabatic section	Length was 250 mm

	Length was 250 mm

Condenser section	Cool water flow was 25°C

	Volumetric flow rate was 1 l/min

Section of economizer	Condition design

Evaporator section	Hot water flow was 80°C

	Volumetric flow rate was 5 l/min

Adiabatic section	Length was 250 mm

	Length was 250 mm

Condenser section	Cool water flow was 25°C

	Volumetric flow rate was 1 l/min


Item	Dimension	Missing values (%)

1. I work hard to keep my HIV a secreta	Disclosure concerns	0.0

2. Most people believe a person who has HIV is dirtya	Public attitudes	3.4

3. Having HIV makes me feel uncleana	Negative self-image	8.6

4. Most people think a person with HIV is disgustinga	Public attitudes	1.7

5. Having HIV makes me feel I'm a bad persona	Negative self-image	0.0

6. Most with HIV are rejected when others learna	Public attitudes	5.2

7. I am very careful whom I tell that I have HIVa	Disclosure concerns	3.4

8. Having HIV in my body feels disgustinga	Negative self-image	0.0

9. I have been hurt by how people reacted to learning I have HIV	Personalized stigma	19.0

10. I worry that people who know I have HIV will tell others	Disclosure concerns	13.8

11. I have stopped socializing with some due to their reactions to my HIV	Personalized stigma	19.0

12. I have lost friends by telling them I have HIV	Personalized stigma	24.1

Item

1. I work hard to keep my HIV a secreta

2. Most people believe a person who has HIV is dirtya

3. Having HIV makes me feel uncleana

4. Most people think a person with HIV is disgustinga

5. Having HIV makes me feel I'm a bad persona

6. Most with HIV are rejected when others learna

7. I am very careful whom I tell that I have HIVa

8. Having HIV in my body feels disgustinga

9. I have been hurt by how people reacted to learning I have HIV

10. I worry that people who know I have HIV will tell others

11. I have stopped socializing with some due to their reactions to my HIV

12. I have lost friends by telling them I have HIV

Dimension	Missing values (%)

Disclosure concerns	0.0

Public attitudes	3.4

Negative self-image	8.6

Public attitudes	1.7

Negative self-image	0.0

Public attitudes	5.2

Disclosure concerns	3.4

Negative self-image	0.0

Personalized stigma	19.0

Disclosure concerns	13.8

Personalized stigma	19.0

Personalized stigma	24.1


	Healthy normal control	Obese control	OHS	OSAS	P

	Med.	Perc.25/75	Med.	Perc.25/75	Med.	Perc.25/75	Med.	Perc.25/75

Trials administered	103.5	81128	117	10728	128	128128	128	102.5128	0.04


Variable	<35	p-value	≥35	p-value

 	Adjusted odds ratio (95% CI)	 	Adjusted odds ratio (95% CI)

a. Adjusted Confounder Model for not having tested for HIV in the past 2 years, stratified by age

Asian ethnicity	2.04 (1.08-3.86)	0.028	0.65 (0.28-1.51)	0.32

English or French as first language	1.29 (0.69-2.43)	0.426	1.28 (0.62-2.66)	0.51

Age (in years) of participate at study enrolment.	0.97 (0.92-1.02)	0.245	1.01 (0.98-1.03)	0.58

IDU ever	0.81 (0.41-1.56)	0.522	0.42 (0.20-0.86)	0.017

At the present time, do you smoke cigarettes?	1.31 (0.84-2.03)	0.234	1.15 (0.68-1.95)	0.60

Not told doctor of male sex partners	5.83 (3.67-9.24)	<0.001	3.47 (1.90-6.35)	<0.001

b. Adjusted Confounder Model for not having tested for Hepatitis C Virus in the past 2 years, stratified by age

Asian ethnicity	2.30 (1.27-4.19)	0.006	1.05 (0.51-2.15)	0.90

English or French as first language	1.25 (0.71-2.22)	0.435	1.14 (0.61-2.13)	0.68

Age (in years) of participate at study enrolment.	0.99 (0.95-1.04)	0.664	1.02 (1.00-1.04)	0.063

Not told doctor of male sex partners	7.06 (4.30-11.60)	<0.001	2.43 (1.41-4.18)	0.001

c. Adjusted Confounder Model for not having tested for syphilis in the past 2 years, stratified by age

Asian ethnicity	0.85 (0.45-1.61)	0.625	0.67 (0.32-1.40)	0.29

English or French as first language	1.19 (0.66-2.15)	0.563	0.81 (0.43-1.52)	0.51

Age (in years) of participate at study enrolment.	0.96 (0.92-1.01)	0.124	0.99 (0.97-1.01)	0.48

IDU ever	1.59 (0.86-2.93)	0.137	1.77 (1.08-2.90)	0.023

At the present time, do you smoke cigarettes?	0.66 (0.44-1.00)	0.048	0.65 (0.43-0.98)	0.038

Not told doctor of male sex partners	0.11 (0.07-0.18)	<0.001	0.24 (0.14-0.42)	<0.001


Variables	Category	(1)

rifEI

Demographic characteristics

Gender	Female (Reference)

Male	−0.019***

Age group	Quartile 4 (56+) (Reference)	Reference

Quartile 1 (18–33)	−0.079***

Quartile 2 (33–43)	−0.022***

Quartile 3 (43–56)	−0.014**

Ethnicity	Ethnic Minority (Reference)

Han	−0.016**

Marital status	Divorced, separated, or widowed (Reference)

Married	−0.083***

Single	−0.075***

Household size		−0.002

Health insurance	Yes = 1; No = 0	0.024***

Socioeconomic status

Per capita household income		−0.054***

Work status	Work = 1; Not working = 0	0.045***

Education degree	Primary education (Reference)

Secondary education	−0.025***

Tertiary education	0.228***

Lifestyle factors

Smoking history	Yes = 1; No = 0	−0.004

Drinking alcohol	Yes = 1; No = 0	0.014**

BMI	Normal weight (Reference)

Underweight	0.095***

Overweight	−0.011

Obese	0.002

Home environment

Tap water	Yes = 1; No = 0	−0.035***

Flush toilet	Yes = 1; No = 0	−0.023***

Region	Eastern (Reference)

Middle	−0.017***

Western	−0.027***

Year	1991 (Reference)

1993	0.022***

1997	0.064***

2000	0.080***

2004	0.065***

2006	0.044***

Constant		0.505***

Observations		31,958


	Aboriginal	Non-Aboriginal

	Had surgery n/N (%)	Had surgery n/N (%)	p-valueb

Comorbiditiesd			0.018

No comorbidities	9/41 (22)	1390/3196 (43)

At least one comorbidity	28/79 (35)	1276/3561 (36)

Socioeconomic disadvantage			0.245

Least and second least disadvantaged	5/15 (33)	1095/2477 (44)

Third least disadvantaged	3/16 (19)	464/1168 (40)

Second most and most disadvantaged	29/89 (33)	1107/3112 (36)


Variable	Training groups	P value‡

	Control groupn = 60Mean (SD)	Endurance n = 59Mean (SD)	Strength n = 60Mean (SD)

Demographic

 Age, years	46 (5)	46 (6)	45 (6)	0.73

 Height, cm	164 (5)	165 (6)	165 (5)	0.74

 Weight, kg	69 (12)	68 (10)	67 (11)	0.64

 Body mass index	26 (4)	25 (3)	25 (3)	0.40

Clinical characteristic

 Duration of neck pain, years	8 (5)	9 (6)	8 (6)	0.30

 Neck pain, mm (VAS†, scale 0-100)	58 (20)	56 (22)	57 (20)	0.89

Variable	Training groups

	Control groupn = 60Mean (SD)	Endurance n = 59Mean (SD)	Strength n = 60Mean (SD)

Demographic

Age, years	46 (5)	46 (6)	45 (6)

Height, cm	164 (5)	165 (6)	165 (5)

Weight, kg	69 (12)	68 (10)	67 (11)

Body mass index	26 (4)	25 (3)	25 (3)

Clinical characteristic

Duration of neck pain, years	8 (5)	9 (6)	8 (6)

Neck pain, mm (VAS†, scale 0-100)	58 (20)	56 (22)	57 (20)


Detection range	Passerinesa	Wadersb	Hooded crow (Corvus cornix)	Gulls	Mallard (Anas platyrhynchos)	Raven (Corvus corax)	Greylag goose (Anser anser)	White‐tailed eagle (Haliaeetus albicilla)

Maximum	2,866	4,377	2,869	3,564	3,103	3,446	3,722	3,643

N	76	33	74	220	11	58	38	725


	mean (SD)

Age, y	31.6 (4.3)

Age at menarche, y	13.2 (1.5)

Pre-pregnancy BMI, kg/m2	24.3 (3.7)

	% (n)

Pre-pregnancy BMI group

 Underweight (BMI < 18.5)	11 (8)

 Normal weight (BMI 18.5 - 24.9)	52 (61)

 Overweight (BMI 25 - 29.9)	30 (36)

 Obese (BMI ≥ 30)	7 (8)

Educational level

 Not completed post high school education	32 (38)

 Completed post high school education	68 (80)

	mean (SD)

Completed post high school education	68 (80)


Shot ID	Dimensions	Treatment	No. of samples analysed

	d [mm]	Weight [g]		C	S


		Status at consent

		High non-tryer	High tryer	Pregnant

		%	%	%

Age, years	<18	0	0	1.4

	18–19	*	0	3.3

	20–34	90.9	83.7	76.5

	35+	*	16.3	18.7

	Mean (standard deviation)	27.7 (4.0)	30.7 (4.1)	29.2 (5.7)

Race/ethnicity	Asian, non-Hispanic	*	*	4.2

	Black, non-Hispanic	*	*	6.4

	Hispanic	22.7	10.2	20.0

	Other^	20.5	20.4	8.0

	White, non-Hispanic	50.0	67.3	61.5

		Status at consent

		High non-tryer

		%

Age, years	<18	0

	18–19	*

	20–34	90.9

	35+	*

	Mean (standard deviation)	27.7 (4.0)

Race/ethnicity	Asian, non-Hispanic	*

	Black, non-Hispanic	*

	Hispanic	22.7

	Other^	20.5

	White, non-Hispanic	50.0


Organism	Degradosome-dependence	PNPase role	References

Yersinia pestis	?	Catalytic activity plays an essential role in cold growth	Rosenzweig et al., 2005

	?	Required for virulence in a catalytic-activity-independent manner	Rosenzweig et al., 2005

	?	S1 domain sufficient for mediating virulence	Rosenzweig et al., 2005

	?	The first 15 aa residues of the S1 domain are dispensable for virulence; however, the first 30 aa residues are required for virulence	Rosenzweig et al., 2007

	?	Amino acid residue F638 within the PNPase S1 domain is required for virulence and cold growth	Rosenzweig et al., 2007

Yersinia pseudotuberculosis	No	S1 and KH domains also contribute to cold growth.	Rosenzweig et al., 2005

	No	Degradosome-independent role in cold growth	Henry et al., 2012

	Yes	Degradosome assembly required for virulence	Yang et al., 2008

	Yes	Degradosome-dependent role in oxidative stress response	Henry et al., 2012

	No	PNPase is dispensable for antibiotic/chemical stress responses	Henry et al., 2012


Number	Outcomes

1	Patient-provider communication

2	Monitor treatment response

3	Detect unrecognised problems

4	Changes to patient health behaviour

5	Changes to patient management

6	Improved patient satisfaction

7	Improved health outcomes

8	Strong & effective quality improvement

9	Increased transparency, accountability, public reporting

10	Better system performance (monitoring, planning, financing; evaluating, responding)

11	Mediating variables on the effect (both at individual and organisation level)

12	Possible subgroup effects

Outcomes

Patient-provider communication

Monitor treatment response

Detect unrecognised problems

Changes to patient health behaviour

Changes to patient management

Improved patient satisfaction

Improved health outcomes

Strong & effective quality improvement

Increased transparency, accountability, public reporting

Better system performance (monitoring, planning, financing; evaluating, responding)

Mediating variables on the effect (both at individual and organisation level)

Possible subgroup effects